Posted on May 2, 2025 and graduate students Yongjia He (Caram group) have been selected for the 2025 cohort of UC President’s Lindau Nobel Laureate Meetings Fellows who will join Nobel laureates from around the world at a scholarly gathering in Lindau 2025) will be themed around circular chemistry artificial intelligence and science diplomacy Funded by UC Investments and UC National Laboratories the fellowship supports travel and expenses for participants to attend the Lindau Nobel Laureate Meetings one of the most celebrated academic exchanges in the world The meetings bring together laureates and the next generation of scientific leaders for a week of dialogue across generations she has been a postdoctoral researcher in Professor Gerard Wong’s group in the UCLA Department of Bioengineering Her research focuses on the biophysical chemistry of cellular behavior bridging molecular-scale machinery at the microscopic level with cellular functions at the mesoscopic level Haleh’s ultimate goal is to identify the integrated principles in the molecular and cellular environment for designing effective therapeutics Yongjia He is a fourth-year physical chemistry graduate student conducting research in Professor Justin Caram’s group She received her bachelor’s degree in physics from Wuhan University in 2020 Her current research explores the photophysical properties of chemical complexes to advance scalable molecular qubits Yongjia’s lifelong goal is to apply quantum technologies for environmental solutions and inspire the next generation of scientists Luca McDermott Catena is a fourth-year organic chemistry graduate student conducting research in Professor Neil Garg’s group He received his bachelor’s degree in biochemistry from Tufts University in 2020 His research is focused on the chemistry of geometrically distorted alkenes as well as the total synthesis of Platonic hydrocarbons Throughout his career he hopes to continue advancing the beautiful field of synthetic organic chemistry Yessica Alejandra Nelson is a fifth-year Ph.D candidate in inorganic chemistry under the guidance of  Professor Alexander Spokoyny Her research focuses on developing synthetic strategies for the vertex-selective functionalization of boron clusters in Chemistry from California State University She advances molecular design and translational science while championing the mentorship of future scientific innovators Excerpted from the University of California Newsroom: Young UC scientists and economists selected for prestigious Nobel laureate meeting The University of California today (April 24) announced the 2025 cohort of UC President’s Lindau Nobel Laureate Meetings Fellows 42 outstanding young scientists and economists from across the UC system who will join Nobel laureates from around the world at two renowned scholarly gatherings in Lindau The 2025 Lindau Meetings will focus on two areas: “This fellowship reflects the University of California’s deep commitment to advancing discovery and preparing the next generation of scientific leaders,” said UC President Michael V “We are proud to support these exceptional students and postdocs as they represent the very best of UC on the world stage.” host 30 to 40 Nobel laureates and approximately 600 early-career researchers from more than 100 countries “These meetings are nothing short of phenomenal,” said UC Chief Investment Officer Jagdeep Singh Bachher the Nobel laureates are generous with their time and wisdom and the energy from all the brilliant young minds in one place is unparalleled.” Since the UC program’s inception six years ago 170 UC students and postdocs have been named fellows — 130 from the 10 UC campuses and 42 from the UC-affiliated national laboratories More than 35,000 young scholars worldwide have taken part in the Lindau program overall since its founding in 1951 The UC fellows are nominated by faculty and selected through a rigorous process that includes essays and approval by the Lindau Foundation in Germany A UC faculty workgroup — including two Nobel Prize winners — helped narrow down the candidates vice president for UC National Laboratories “Our national labs are dedicated to tackling the world’s most pressing scientific challenges — and that mission begins with cultivating extraordinary talent,” said Yu and collaborative spirit we need to shape the future of science and innovation.” This year’s fellows from UC campuses for the chemistry meetings are:Sagar Bhattacharya (UC San Francisco) The chemistry fellows representing the national laboratories are as follows:Manjeet Chhetri (Los Alamos) UCLA Department of Chemistry & Biochemistry Δdocument.getElementById( "ak_js_1" ).setAttribute( "value" University of California © 2025 UC Regents All 5 Releases Beth Ryan, a Chemistry and Chemical Biology graduate student in the Weill Institute’s Baskin Lab has been chosen as a Young Scientist invited to attend the 74th Lindau Nobel Laureate Meeting on Chemistry in June 2025 Nobel Laureates in Chemistry and 600 young scientists from around the world will come together in Lindau Beth’s research involves engineering novel optogenetic (light-controlled) enzymes to manipulate the properties of cellular membranes Read the full story on the Weill Institute website.  In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al found that use of the hypoxia-inducible factor-2α inhibitor belzutifan was associated with maintained benefit in patients with von Hippel–Lindau disease–associated renal cell carcinoma The initial report from the trial supported approval of belzutifan in this setting and the United States enrolled between May 2018 and March 2019 and received belzutifan at 120 mg once-daily until progression or unacceptable toxicity The primary endpoint was the proportion of patients with objective response on independent review committee assessment The current report provides outcomes after median follow-up of 49.9 months (interquartile range = 48.9–52.2 months) Objective response was observed in 41 (67% 95% confidence interval [CI] = 54%–79%) of 61 patients Median duration of response was not reached (95% CI = 41.3 months to not reached); 71.5% of responders had ongoing response at the last measurement at 42 months Median progression-free survival was 49.8 months (95% CI = 49.8 months to not reached) grade 3 treatment-related adverse events were observed in 18% of patients most commonly anemia (11%) and fatigue (5%); no treatment-related grade 4 or 5 adverse events were observed Serious treatment-related adverse events were observed in 7% of patients The investigators concluded: “Updated results support the use of belzutifan as systemic treatment for von Hippel-Lindau disease-associated renal cell carcinoma.” Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, is the corresponding author for The Lancet Oncology article Disclosure: The study was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co, and others. For full disclosures of all study authors, visit thelancet.com/journals/lanconc Trachte’s Recently Retired National Sales ManagerThe Many Lives of Self-Storage Development ‘Sensei’ Jamie Lindau Trachte’s Recently Retired National Sales ManagerEvery industry has standout individuals who aren’t only known by name but by what they’ve contributed to the business Jamie Lindau is such a person in self-storage Before retiring from his post as national sales director of Trachte Building Systems in December he helped thousands of developers and owners presented hundreds of development-related seminars and spearheaded countless product innovations Read about his many “lives” and future plans If you've ventured into the realm of self-storage He’s been a towering figure in the industry dedicating more than 50 years to developers owners and managers across Canada and the U.S As he steps away from his role as national sales manager for Trachte Building Systems to enjoy retirement here are the highlights of his incredible career and his lasting mark on the products he designed people he assisted and industry he helped to build Lindau’s self-storage journey began at the tender age of 15 when he worked in the Trachte plant and witnessed the inception of the first all-galvanized This early exposure forged a foundation for what would become a remarkable career marked by innovation leadership and an unwavering commitment to education Jamie has presented more than 320 self-storage seminars becoming the face of Trachte’s outreach and a key driver in advancing industry knowledge His “Building Blocks of Self-Storage” events have been attended more than 25,000 students helping them launch and enhance their facilities Lindau’s profound impact is reflected in the success stories of many developers and owners who say he enabled them to realize dreams far beyond their expectations Related:S Jones Containers of the UK Launches Paint-Restoration Product for Portable Self-Storage Units Lindau’s commitment to education and his ability to translate knowledge into tangible success have led to other incredible achievements for Trachte He directed hundreds of product improvements over his career and was instrumental in various innovations that have reshaped self-storage facility design and construction One of the most significant came in 1986 with the outside eave angle His contributions have not only enhanced the functionality and cost-efficiency of storage buildings but have set new standards Lindau’s family owned self-storage facilities in Florida and he eventually developed properties in Madison This played a pivotal role in the evolution of facility design as his projects often served as test sites for Trachte products They also provided much of the firsthand knowledge Lindau would share in his seminars Lindau’s career is distinguished by his customer-first approach through which he demonstrated steadfast advocacy for his clients He consistently prioritized the success of new entrants to the business over personal sales gains he was known for telling customers and coworkers what they needed to hear ensuring honesty and integrity in all interactions Related:Colliers Launches The Stockhausen-Hernandez Self-Storage Team to Serve Mid-Atlantic, Southeast Lindau’s dedication reached beyond Trachte He nurtured the careers of professionals in related sectors such as security He introduced them to self-storage and mentored them toward expert status “Jamie kept his hand on the pulse of the industry his mentorship and genuine care have guided many of us toward healthy and prosperous careers in storage,” says Benjamin Burkhart owner of StorageStudy.com and ProSafe Storage Lindau’s expertise in self-storage is further exemplified by his significant contributions to educational content He’s truly the industry’s “original” influencer A quick YouTube search reveals numerous videos featuring his expertise which have collectively garnered hundreds of thousands of views Lindau has a passion for making things better he refused to restrict progress in the name of perfection especially in early attempts at scripted education videos that didn’t meet viewer expectations It quickly became clear that the best way to produce a session with him was to simply choose a topic visit a storage facility and record him speaking candidly This impromptu style led to the nickname “King of Wing,” adding to his persona as a dynamic and effective communicator Related:Harbor Lockers Offers New Ancillary Opportunity to Self-Storage Operators Lindau’s zest for adventure transcends the realm of self-storage extending into a profound passion for travel and exploration he has a penchant for embarking on the most daring of escapades with no plan at all whether it's sailing across the turquoise waters of the Caribbean fishing the deep waters off Panama or navigating the icy expanse of Antarctica Lindau isn’t just interested; he's all in filled with tales that range from close encounters with monkeys to dramatic helicopter rescues He’s truly a unique character; the only person you might know whose vacation stories could as easily belong in an adventure magazine as in a casual conversation Lindau’s approach to work-related travel was just as bold He’s never one to shy away from logging extra miles only he could convincingly argue that Waterloo is on route from Indiana to Madison—a testament to his willingness to go the extra mile His dedication to spreading knowledge took him across the country with his seminar travels reaching 46 states and amassing millions of air miles and hours of windshield time This extensive travel underscores Lindau’s unwavering commitment to reaching and assisting as many potential self-storage operators as possible his deep-seated knowledge and enthusiasm for the industry have shone through earning him respect and admiration of his peers and mentees Lindau’s involvement with Inside Self-Storage and other industry organizations has been characterized by his active participation and contributions as a speaker at national events He has consistently provided valuable insight drawing from his extensive experience and deep understanding of the industry owner of RJK & Associates and Bearcat Storage has known Lindau for more than 38 years He describes Lindau as the trusted resource for everything storage unit mix and roof styles with ease and then guide the discussion through financial performance in such a way that offered encouragement to the newest developers,” Krumdieck says Despite his official retirement from Trachte in December 2023 Lindau has a passion for self-storage that remains undiminished he continued sharing his valuable knowledge through seminars He’s also actively involved in facility management with his children His ongoing dedication and willingness to provide guidance have made him an invaluable industry contributor influencing best practices and inspiring innovation across the self-storage community Few can claim to have worked every job in the self-storage industry or to have been at the inception of what has now become a vital part of the American economy embodying a lifetime of commitment and excellence The 2 Prongs of an Effective Self-Storage Website: Search Engine Optimization and User Experience Bringing Added Value: How Self-Storage Managers Can Optimize Their Impact on Facility Performance Scottish Investment Firm SRA Ventures Acquires Boxxs Self-Store Crews Demolish Julie Street Self Storage in Sunbury This website is using a security service to protect itself from online attacks The action you just performed triggered the security solution There are several actions that could trigger this block including submitting a certain word or phrase You can email the site owner to let them know you were blocked Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page are preparing for a global scientific exchange in Lindau A group of scientists who will be attending this year’s Lindau Nobel Laureate Meetings in Germany visited the Texas A&M University campus last week for a two-day workshop related to the prestigious event A select group of young scientists gathered at Texas A&M University last week in preparation for the upcoming 73rd Nobel Laureate Meetings in Lindau The young scientists — a total of 32 students and post-doctoral researchers from across the country — will join more than 600 of their peers from around the world at this year’s meetings Seven students and one post-doctoral researcher from Texas A&M will be among the participants The scientists were nominated to participate in the gathering by their institutions and then selected by a Lindau’s scientific review panel who recently completed a master’s degree at the University of Michigan said the workshop on campus was a great opportunity to meet peers and faculty and learn about what motivated their interest in their research university distinguished professor of veterinary medicine and faculty liaison for the Office of the Vice President for Research chats with students participating in the Lindau Nobel Laureate Meetings during a tour of the Texas A&M University campus “What I keep noticing in their stories is that innovative scientists often encounter initial rejection of their ideas,” Rudra said “I am always inspired by how people persevere through those kinds of challenges we’re going to get to meet people who overcame those challenges and conducted research that changed the world The campus visit was coordinated by the Office of the Provost in collaboration with the Division of Research the Office for Faculty Affairs and the Hagler Institute for Advanced Study The two-day event represents one aspect of a larger initiative at Texas A&M The university has reached a four-year agreement with the Lindau Nobel Laureate Meetings Foundation to be one of the organization’s main U.S academic partners outside California; the University of California System has a similar agreement with Lindau to provide opportunities for young scientists from California Texas A&M will conduct a first round of nomination reviews before forwarding selected nominees on to the Lindau scientific review panel to make final decisions and extend invites to the annual meeting The university will then host a pre-Lindau Meeting preparatory session on campus and support the travel for a number of those invited Texas A&M will support 21 of the 32 students and post-docs selected to attend the Lindau Nobel Laureate Meetings The other 11 will be supported by corporate partner Amgen Texas A&M will host “International Day” at Lindau which opens with a partner breakfast and panel discussion on the role of physics in solving the global problems of the 21st century featuring Nobel Laureate Bill Phillips and two faculty and one young scientist from Texas A&M The day will conclude with cross-cultural sharing of food and activities “Texas A&M is filling an important need in the U.S.,” Steiner said academic institution doing what we’re doing.” executive vice president and provost at Texas A&M said it was an honor to host the scholars to help them prepare for the meeting in Germany “Attending a Nobel Laureate Meeting is transformational for a young scientist We’re giving the most promising students and post-docs at Texas A&M and around the country a chance at a potentially life- and career-changing experience and we’re preparing them to make the most of that experience,” Sams said we get an opportunity to showcase our university by bringing young scholars from around the country to our campus and showing them all our university has to offer then sending them to Lindau as a cohort supported by Texas A&M.” The Lindau Nobel Laureate Meetings provide an international forum for intellectual exchange and collaboration discussions and workshops that cover a range of scientific disciplines with a meeting dedicated to economics every three years nearly 40 Nobel Laureates in physics will be in attendance Hanna Dattilo takes a photo during a tour of the Cyclotron Institute on the Texas A&M University campus a doctoral student at Vanderbilt University is among a group of scholars attending this summer’s Lindau Nobel Laureate Meetings in Germany said she is most interested in the exchange of ideas with such accomplished researchers “Events like this and Lindau,” Dattilo said “are hallmarks of what collaboration looks like and they contradict the stereotype of the mad scientist working alone in a lab Working together and sharing ideas and insights is how we move science forward.” Texas A&M students said they enjoyed having the workshop on campus and are proud that Texas A&M has partnered with Lindau “These two days have been like a crash course in cutting-edge research,” said David Thomas and having a small community will make it easier to interact with the larger community at Lindau a Texas A&M doctoral student in materials science and engineering said he was excited about the university’s effort through the initiative to connect students and the university with the international scientific community “I am interested in philosophical questions surrounding physics,” Strasser said “I have already been blown away by the diversity of ideas on this topic just from the students and post-docs I’ve met here I’m excited to see the perspectives from people of different cultures I’ll encounter at the meeting in Lindau.” Sams said he was pleased that the students and post-docs were getting so much out of the workshop and were excited for their upcoming trip “We hope we are building lifelong relationships between our university and these future scholars they will be faculty researchers representing Texas A&M as Nobel Laureates.” Students and Post-Docs Selected to Attend the 73rd Lindau Nobel Laureate Meeting Students and Post-Docs Attending the 73rd Lindau Nobel Laureate Meeting and the Pre-Meeting Workshop Spring graduations will be celebrated May 8-10 across nine ceremonies at Reed Arena The annual awards recognize individual staff members teams and student employees for their contributions to the university community The Friars honor their beloved dachshunds and support Texas A&M’s veterinary hospital through a heartfelt gift that reflects their love for animals and the Aggie Spirit watch videos and discover how Texas A&M University is shaping an innovative more secure future for the citizens of Texas and the world It would help us if you could report a broken page, please let us know through the IT Service Desk Please make a note of where you were when you clicked the link and the resources you were seeking to find Ten early-career researchers from Australia will be heading to Lindau Germany this year to attend the prestigious Lindau Nobel Laureate Meeting The 74th Lindau Nobel Laureate Meeting dedicated to chemistry and held from 29 June to 4 July 2025 is expected to bring together over 30 Nobel Laureates and 630 young scientists from 84 countries The Australian delegation’s participation in the Lindau Nobel Laureate Meetings is proudly supported through the Science and Industry Endowment Fund (SIEF) and administered by the Australian Academy of Science (AAS) The SIEF–AAS Lindau Fellows receive a grant to enable their attendance at the event and to take part in the SIEF Research Innovation Tour in Berlin showcasing some of Germany’s finest research and development facilities related to chemistry The delegation will be led by Academy Fellow and Foreign Secretary Professor Frances Separovic The 10 PhD candidates and postdoctoral researchers selected to attend the 2025 meeting are: The meeting will provide a unique opportunity for these exceptional early-career scientists to share their research and gain inspiration from fellow emerging scientists and Nobel Laureates Connect with us 95% of patients who received the treatment experienced no tumour growth over two years The National Health Service (NHS) England has announced the availability of MSD UK’s belzutifan a take-at-home pill for patients with von Hippel-Lindau (VHL) disease The move builds on a positive recommendation from the UK National Institute for Health and Care Excellence (NICE) Belzutifan is the first therapy to receive approval as a non-surgical treatment option for this life-threatening genetic condition The pill has shown promising results in clinical trials with 95% of patients experiencing no tumour growth over two years and 56% reporting a reduction in tumour size which is administered orally three times a day simultaneously targets three different types of tumours It operates by hindering a protein that deprives cells of oxygen a process that can cause normal cells to become tumorous belzutifan prevents the growth of new tumours Don’t let policy changes catch you off guard Stay proactive with real-time data and expert analysis As NHS England enters a commercial agreement with MSD UK for belzutifan around 100 patients are expected to benefit from the therapy in the first year The drug will be made available in the country through NHS England’s Cancer Drugs Fund NHS cancer national clinical director professor Peter Johnson stated: “This inherited illness is a shadow which hangs over entire families who live with the fear of tumours growing and needing major surgery on many occasions is the first of its kind for this terrible condition and patients with von Hippel-Lindau syndrome now have a different treatment option which they can take in the comfort of their homes if they need it “It promises to improve the quality of life not just for those facing this disorder and is a huge step forward in the treatment of this disease.” Give your business an edge with our leading industry insights View all newsletters from across the GlobalData Media network All 5 Releases As reported in The Lancet Oncology by Iliopoulos et al updated findings from the phase II LITESPARK-004 trial support the efficacy of belzutifan in patients with von Hippel-Lindau (VHL) disease–associated CNS hemangioblastomas 50 patients with CNS hemangioblastomas (total of 184 lesions) enrolled between May 2018 and March 2019 from sites in the United States and United Kingdom received belzutifan at 120 mg once daily until disease progression or unacceptable toxicity Patients had received no prior systemic therapy The primary outcome measure was objective response on independent review committee assessment The initial report from the study showed clinically meaningful activity of belzutifan; the current report includes 16 additional months of follow-up Median follow-up was 38.0 months (interquartile range [IQR] = 36.7–40.1 months) in this analysis The median duration of treatment was 37.4 months (IQR = 36.1–39.5 months) Response was assessed using two approaches all measurable (≥ 1 cm maximum diameter) or nonmeasurable lesions at baseline were evaluated including both the solid lesion and associated cystic component if present 95% confidence interval [CI] = 30%–59%) of 50 patients had objective response An additional 23 patients (46%) had stable disease Median duration of response was not reached (95% CI = 30.9 months to not reached) only baseline lesions with a measurable (≥ 1 cm maximum diameter) solid lesion were evaluated objective response was observed in 19 (76% An additional 5 patients (20%) had stable disease Median response duration was not reached (95% CI = 33.8 months to not reached) Grade ≥ 3 adverse events occurred in 23 patients (46%) Grade 3 adverse events occurred in 19 (38%) and grade 4 adverse events occurred in 2 patients (4%; retinal vein occlusion and embolism) Adverse events led to death in two patients (suicide and multiple toxicities) with neither death considered related to treatment The investigators concluded: “Belzutifan showed meaningful antitumour activity in VHL disease–associated CNS haemangioblastomas that was sustained for more than 3 years of treatment These results continue to support belzutifan as a systemic treatment option for patients with VHL disease–related CNS haemangioblastomas.” of Massachusetts General Hospital Cancer Center and Harvard Medical School is the corresponding author of The Lancet Oncology article Disclosure: The study was funded by Merck Sharp & Dohme, National Institutes of Health, and National Cancer Institute. For full disclosures of the study authors, visit www.thelancet.com Metrics details The RE1 silencing transcription factor (REST) is a driver of sonic hedgehog (SHH) medulloblastoma genesis Our previous studies showed that REST enhances cell proliferation metastasis and vascular growth and blocks neuronal differentiation to drive progression of SHH medulloblastoma tumors we demonstrate that REST promotes autophagy a pathway that is found to be significantly enriched in human medulloblastoma tumors relative to normal cerebella REST elevation is strongly correlated with increased expression of the hypoxia-inducible factor 1-alpha (HIF1α)—a positive regulator of autophagy and with reduced expression of the von Hippel-Lindau (VHL) tumor suppressor protein – a component of an E3 ligase complex that ubiquitinates HIF1α Human SHH-medulloblastoma tumors with higher REST expression exhibit nuclear localization of HIF1α in contrast to its cytoplasmic localization in low-REST tumors REST knockdown promotes an increase in VHL levels and a decrease in cytoplasmic HIF1α protein levels REST elevation causes a decline in VHL levels resulting in a reduction in HIF1α ubiquitination and an increase in autophagy flux These data suggest that REST elevation promotes autophagy in SHH medulloblastoma cells by modulating HIF1α ubiquitination and stability in a VHL-dependent manner our study is one of the first to connect VHL to REST-dependent control of autophagy in a subset of medulloblastomas REST's role in autophagy seems to be cell-context and disease-specific The data described in the current work suggests that REST-dependent decline in the levels of the von Hippel Lindau (VHL) tumor suppressor protein—a HIFα-specific E3 ubiquitin ligase promotes stabilization and nuclear localization of HIF1α to drive autophagy in SHH-MB cells The gene expression profile of tumors from MB patients was analyzed using previously published publicly available RNAseq (GSE148389) and microarray (GSE202043, GSE124814, and GSE85217) datasets. Differential expression of genes and unsupervised clustering analysis was performed using the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) A value of p < 0.05 was considered significant Gene ontology p-values were not corrected for multiple testing Daoy and UW228 were used here due to differences in REST expression Daoy cells were purchased from the American Type Culture Collection (Manassas) John Silber at the University of Washington Both cell lines were maintained in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal bovine serum (Sigma Aldrich) 1% Antibiotic–Antimycotic (Thermo Fisher Scientific) and 1% sodium pyruvate (Thermo Fisher Scientific) and grown in a humid environment at 37 °C with 5% CO2 Mouse brain tissues were fixed in 10% buffered formalin phosphate for 48 hours and embedded in paraffin Eight-micrometer-thick brain sections were used for IHC analysis Sections were deparaffinized with heat and xylene and rehydrated with ethanol and water Antigen retrieval was performed in citrate antigen retrieval buffer (pH 6) for 30 minutes at 95 ºC in the PT module (ThermoFisher) Sections were washed with 0.1% Tween-20 in PBS (PBST) and then treated with 3% H2O2 solution for 10 min to block endogenous peroxidase Nonspecific binding of rabbit and mouse antibodies was blocked with 1% normal goat serum and a solution provided in the Mouse-on-Mouse kit (MOM kit Sections were then incubated with primary antibodies as indicated below in blocking buffer at 4 °C overnight Primary antibody was detected using a biotinylated secondary antibody provided with the ABC or MOM kit and then incubated with streptavidin-HRP (ABC kit Vector labs) according to the manufacturers’ instructions All incubations were performed under humidified conditions slides were visualized under a Nikon ECLIPSE E200 microscope and 40x magnification using an Olympus SC100 camera Analyses were performed using Olympus cellSens Entry software The following antibodies were used: rabbit anti-REST Embryonic kidney (HEK) 293 T cells were co-transfected with a lentiviral vector (Phage -ef1α-IRES-GFP) backbone or a construct expressing the gene of interest along with packaging plasmid (PAX2) and envelope plasmid (MD2) Lentiviral particles were collected 48 h post-transfection Cells were transduced with the collected viral supernatant in the presence of Polybrene (8 μg/mL) and incubated for 48 h Infected cells were then cultured in a medium containing 2 μg/mL puromycin for up to 1 week for selection Cells extracts were prepared for Western blot analysis by incubating the cells in lysis buffer (50 mM Tris–HCl pH 8.0 and protease/phosphatase inhibitors) for 30 min on ice The lysates were clarified by centrifugation at 13,000×g for 10 min at 4C and the supernatants were collected and boiled in Laemmli buffer (Bio-Rad) Proteins were separated by electrophoresis on 10% SDS–polyacrylamide gels transferred to Hybond-P polyvinylidene difluoride (PVDF) membranes (GE Healthcare) and analyzed by Western blotting with the indicated primary antibodies and HRP-conjugated goat anti-mouse or anti-rabbit secondary antibodies (GE) Protein bands were developed using SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific) and detected using Kodak Medical X-Ray Processor 104 (Eastman Kodak Company) and ChemiDoc Touch Imaging System (Bio-Rad) Images were analyzed using Image Lab software version 5.2.1 (Bio-Rad) The following primary antibodies were used: rabbit anti-REST Cat no# PA5-27322); rabbit anti-Histone H3 To evaluate the effect of Bafilomycin A1 (Cell Signaling Technology Cat no# 54645S) and Hydroxychloroquine (Cell Signaling Technology cells were seeded in a 96-well plate at a density of 5 × 10^3 cells per well and then treated with vehicle [0.2% dimethyl sulfoxide (DMSO)] or different concentrations of the above drugs for 48 and 72 h Cell viability was measured by MTT assays and absorbance measurements were carried out at 570 nm using the CLSRIOStar Plus Plate Reader cells were washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) for 5–7 min cells were permeabilized with 0.5% Triton X-100 for 5–7 min and washed once again with PBS followed by blocking for 1 h at room temperature using 1% bovine serum albumin (BSA) primary antibodies (Anti-LC3B 1:1000—Cat no# NB600; Novus Biologicals) were added to the coverslips at dilutions stated below and incubated overnight at 4 °C in a moist and humid chamber Cells were washed thrice with PBS and incubated with secondary antibodies (Thermofisher; Cat no# A-21246) for 1 h at room temperature Stained cells were imaged using a Leica DMi8 fluorescence microscope cultured cells were fixed with a solution containing 0.1% glutaraldehyde plus 2% paraformaldehyde in 0.1 M PBS then washed with sterile water overnight at 4 °C samples were dehydrated with increasing concentrations of ethanol embedded in Lowicryl resin and subjected to UV polymerization for 2 days at − 20 °C followed by 3 days at room temperature Post-embedding immunogold labeling was carried out on 70 nm ultrathin sections on formvar coated nickel grids to detect the presence of LC3B These ultrathin sections were conditioned in Millipore-filtered block reagent consists of 0.05 M glycine and 2% BSA in 0.1 M PBS pH 7.3 for a duration of 30 min at room temperature Sections were then incubated overnight at 4 °C with a primary antibody against anti-LC3B (1:100 Novus Biologicals; Cat no# NB600) in blocking buffer sections were incubated for 2 h at room temperature with a secondary antibody conjugated to gold particles (dilution: 1:20 Cat no# 111-195-144) diluted to a ratio of 1:40 in blocking buffer Samples were rinsed in PBS and fixed with 2.5% glutaraldehyde (v/v) in PBS for a period of 15 min and subjected to uranyl acetate and lead citrate for contrast staining Electron micrographs were captured using a JEM 1010 transmission electron microscope (JEOL Digital images were obtained using the AMT Imaging System (Advanced Microscopy Techniques Corp Daoy and UW228 cells were washed with ice-cold PBS and lysed in mild lysis buffer (50 mM Tris–HCl pH 7.5 5 mM EDTA) with a protease inhibitor cocktail (Roche) and phosphatase inhibitor (Sigma) and sonicated Lysates were incubated with mouse IgG (as a control) anti-HIF1α (Novus Biologicals; NB100-105) primary antibody overnight at 4 °C and then incubated with A/G ultralink resin (Thermo Fisher Scientific) for 1.5 h at 4 °C transferred onto PVDF membranes and analyzed by Western blotting using anti-HIF1α (Novus Biologicals; Cat no# NB100-134) anti-ubiquitin (Cell Signaling Technology; Cat no# 3933) and anti-VHL (Novus biologicals; NB100-41384) antibodies The list of autophagy-related genes included for clustering analysis is provided in Spreadsheet S1 Autophagy is an enriched pathway in MB (a) Pathway enrichment analysis shows enriched pathways in MB subgroups compared to normal samples Analysis was performed with the GSE124814 dataset (b) Clustering analysis was done using the R2 genome analysis and visualization platform to examine the expression patterns of autophagy-related genes across four distinct subgroups of MBs (GSE85217) (c) Box plot showing mRNA expression of REST in SHH-MB patients (GSE85217) categorized as high REST (HR) and low REST (LR) samples (d) Heatmap shows the clustering of HR and LR SHH-MB samples based on the expression of autophagy-related genes in GSE85217 These data strongly suggest autophagy-related genes are differentially expressed in HR- and LR-SHH MB samples It also raises the possibility that REST may control autophagy in SHH MBs (a) Immunohistochemical staining of patient-derived orthotopic xenografts (PDOX) with high and low REST expression for autophagy markers Scale bar: [20 µm for H&E and 10 µm for immunohistochemistry] (b) Western blot analysis of autophagy markers in PDOX samples The densitometry ratios of LC3B-II/LC3B-I are shown below the Western blot images Daoy and UW228 to show (c) basal levels of REST LC3B-II and p62 and changes in their levels following (d) REST knockdown and (e) overexpression The densitometry ratio of LC3B-II/LC3B-I (top row) and p62/Actin (bottom row) is shown below the Western blot image (f) Immunofluorescence images of parental and REST-overexpressing isogenic cells showing LC3B staining Zoomed-in images highlight punctate staining of LC3B in REST-overexpressing cells Scale bar: [25 µm] (g) Transmission Electron Microscopy (TEM) images displaying immunogold labeling of LC3B in parental and REST-overexpressing UW228 cells The zoomed-in images show the localization of LC3B in an autophagosome (arrow) HIF1α is required for REST-dependent autophagy in SHH MBs (a) Volcano plot showing the expression of positive regulators of autophagy including HIF1α in HR compared to LR SHH-MB samples (GSE85217) (b) Box plot showing mRNA expression of HIF1α in HR and LR SHH-MB samples (GSE85217) (c) Scatter plot of correlation of REST mRNA expression and HIF1α mRNA expression (GSE85217; n = 223) (d) Immunohistochemical staining of HIF1α in SHH-MB PDOX with high and low expression of REST Daoy and UW228 to show (e) the basal levels of REST and HIF1α and changes in their levels following (f) REST knockdown or (g) overexpression LC3B-II and p62 level after siRNA (h) or pharmacological (Chrysin) ablation of HIF1α in parental and (i) REST-overexpressing Daoy and UW228 cells Densitometry ratios of LC3B-II/LC3B-I (top row) and p62/Actin (bottom row) are shown below the Western blot images Together these finding suggest that HIF1α loss may block the maturation of autophagosomes REST elevation causes a decline in VHL expression (a) Scatter plot of correlation of REST mRNA expression and VHL mRNA expression (GSE85217; n = 223) (b) Box plot to show significant decrease (p = 0.0006) of VHL expression in HR samples compared to LR SHH-MBs (GSE85217) (c) Kaplan–Meier plot to demonstrate significant differences in overall survival of SHH-MB patients based on the relative expression of REST and VHL in the tumors (GSE85217) (d) Immunohistochemical staining of VHL in SHH-MB PDOX with high and low expression of REST (e) Western blot showing expression of VHL in Daoy and UW228 cell lines Changes in VHL levels were studied by Western blotting after siRNA-mediated REST silencing (f) and REST overexpression (g) in Daoy and UW228 cells (h) Co-immunoprecipitation of HIF1α and VHL in isogenic parental and REST overexpressing Daoy and UW228 cells Cell lysates were subjected to immunoprecipitation with anti-HIF1α antibody followed by Western blot analysis with anti-ubiquitin (Ub) and anti-VHL antibodies We show that autophagy supports tumor cell survival These finding suggest that REST contributes to the cellular response to hypoxia Overview of REST-mediated control of autophagy in SHH-MBs Model figure shows REST promotes HIF1α stabilization by preventing its VHL-mediated ubiquitination and proteasomal degradation (Created with BioRender.com) Given the involvement of REST in metastasis it would be important to ask if autophagy plays a role in the therapeutic sensitivity of REST-high metastatic SHH-MBs and if treatment response can be augmented by targeting autophagy we show here that autophagy is dysregulated in MB tumors and that the molecules engaged in effecting autophagy may be subtype-specific We have identified a novel role for REST in modulating VHL and HIF1α protein levels as well as HIF1α sub-cellular localization in SHH-MBs potentially in a metastatic subpopulation of SHH-MBs Medulloblastoma: Current perspectives and recent advances Pediatric versus adult medulloblastoma: Towards a definition that goes beyond age Differential patterns of metastatic dissemination across medulloblastoma subgroups and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: A multicentre cohort study Tailoring medulloblastoma treatment through genomics: Making a change REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis Baldelli, P. & Meldolesi, J. The transcription repressor REST in adult neurons: Physiology, pathology, and diseases. eNeuro https://doi.org/10.1523/ENEURO.0010-15.2015 (2015) Dobson, T. H. W. et al. The transcriptional repressor REST drives lineage-stage-specific chromatin compaction at Ptch1 and AKT hyperactivation in medulloblastoma. Sci. Signal. https://doi.org/10.1126/scisignal.aan8680 (2019) REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration 06 Biological Sciences 0604 Genetics Autophagy: A critical regulator of cellular metabolism and homeostasis Autophagy in the regulation of tissue differentiation and homeostasis The relationship between autophagy and brain plasticity in neurological diseases Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinson’s disease patients REST and stress resistance in aging and Alzheimer’s disease High glucose and palmitic acid induces neuronal senescence by NRSF/REST elevation and the subsequent mTOR-related autophagy suppression Rocchi, A. et al. REST/NRSF deficiency impairs autophagy and leads to cellular senescence in neurons. Aging Cell https://doi.org/10.1111/acel.13471 (2021) Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma Nucleoporin TPR (translocated promoter region nuclear basket protein) upregulation alters MTOR-HSF1 trails and suppresses autophagy induction in ependymoma Pu, Y., Wang, J. & Wang, S. Role of autophagy in drug resistance and regulation of osteosarcoma (Review). Mol. Clin. Oncol. https://doi.org/10.3892/mco.2022.2505 (2022) Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence Bharambe, H. S. et al. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas. Acta Neuropathol. Commun. https://doi.org/10.1186/s40478-019-0697-3 (2019) Restoration of miR-30a expression inhibits growth tumorigenicity of medulloblastoma cells accompanied by autophagy inhibition HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation Determination of a tumor-promoting microenvironment in recurrent medulloblastoma: A multi-omics study of cerebrospinal fluid Reactive oxygen species signaling promotes hypoxia-inducible factor 1-α stabilization in sonic hedgehog-driven cerebellar progenitor cell proliferation Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma REST: An epigenetic regulator of neuronal stress responses in the young and ageing brain Mild inactivation of RE-1 silencing transcription factor (REST) reduces susceptibility to Kainic acid-induced seizures Regulation of neuronal autophagy and the implications in neurodegenerative diseases Hypoxia signals autophagy in tumor cells via AMPK activity Chrysin a promising anticancer agent: Recent perspectives Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein The transcriptional landscape of Shh medulloblastoma Deconstructing sonic hedgehog medulloblastoma: molecular subtypes Smit, M. J. et al. The developmental stage of the medulloblastoma cell-of-origin restricts sonic hedgehog pathway usage and drug sensitivity. J. Cell Sci. https://doi.org/10.1242/jcs.258608 (2022) Sonic hedgehog signaling in cerebellar development and cancer The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation Oxygen tension and the VHL-Hif1α pathway determine onset of neuronal polarization and cerebellar germinal zone exit REST promotes ETS1-dependent vascular growth in medulloblastoma Hypoxia-induced autophagy is involved in radioresistance via HIF1A-associated Beclin-1 in glioblastoma multiforme Shining a light on autophagy in neurodegenerative diseases Autophagy in neurodegenerative diseases: pathogenesis and therapy Phosphorylation of p62 by AMP-activated protein kinase mediates autophagic cell death in adult hippocampal neural stem cells Autophagic death of adult hippocampal neural stem cells following insulin withdrawal FIP200 is required for maintenance and differentiation of postnatal neural stem cells HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors 1 HIF1α-BNIP3-mediated mitophagy protects against renal fibrosis by decreasing ROS and inhibiting activation of the NLRP3 inflammasome The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death TET3 is recruited by REST for context-specific hydroxymethylation and induction of gene expression REST is a hypoxia-responsive transcriptional repressor BC-box protein domain-related mechanism for VHL protein degradation A case of von Hippel-Lindau disease with colorectal adenocarcinoma renal cell carcinoma and hemangioblastomas Implications of Von Hippel-Lindau syndrome and renal cell carcinoma Stegeman, H. et al. Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: Implications for future treatment strategies. Future Sci. OA https://doi.org/10.4155/fso.15.84 (2016) Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis Dong, S. et al. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J. Exp. Clin. Cancer Res. https://doi.org/10.1186/s13046-021-02229-6 (2022) Oxidative stress and autophagy: The clash between damage and metabolic needs mTOR inhibits autophagy by controlling ULK1 ubiquitylation self-association and function through AMBRA1 and TRAF6 Autophagy and the integrated stress response Download references This work was supported by funding from the Addis Faith Foundation to VG and the CCSG grant NIH P30CA016672 grant to The University of Texas MD Anderson Cancer Center and the High-Resolution Electron Microscopy Facility for electron microscopy imaging The University of Texas MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center and UTHealth Graduate School for Biomedical Sciences execution and interpretation of experiments The authors declare no competing interests Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Download citation DOI: https://doi.org/10.1038/s41598-024-63371-7 Anyone you share the following link with will be able to read this content: a shareable link is not currently available for this article Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research The views and opinions expressed on this site are solely those of the original authors. They do not necessarily represent the views of BMJ and should not be used to replace medical advice. Please see our full website terms and conditions All BMJ blog posts are posted under a CC-BY-NC licence BMJ Journals Yashika Kapoor a postdoctoral fellow in physics from Arts & Sciences at Washington University in St has been selected to participate in the 73rd annual Lindau Nobel Laureate Meeting Kapoor is an experimental condensed-matter physicist investigating novel electronic phases in two-dimensional Van der Waals materials She is one of 650 young scientists selected from around the world to participate in the conference, which will also have 30 Nobel laureates in attendance. The conference will focus on the impact of physics in the future of energy supply, artificial intelligence and quantum research.Read more on the Department of Physics website Notables Awards & Notables Physical Sciences Science & Technology Read more stories from Arts & Sciences Visit Arts & Sciences Child tuition benefit webinar offered Flags lowered in memory of Pope Francis WashU moves training to Workday Learning Biology students win annual awards McKelvey Engineering honors 2025 distinguished alumni Student Life wins best newspaper honor at Missouri College Media awards Brad Warner, professor of pediatric surgery, 66 Julian Fleischman, associate professor emeritus, 91 William D. Owens, MD, professor emeritus of anesthesiology, 85 Understanding genetic factors behind a pediatric brain tumor Study examines overlap in causes of cancer, neurodevelopmental disorders Pollina honored for innovations in neuroscience 05.05.25 04.28.25 04.14.25 Wilmetta Toliver-Diallo Jhan Carlos Salazar Juliane Bubeck Wardenburg Who Knew WashU? 1.27.21 Who Knew WashU? 1.13.21 Who Knew WashU? 12.9.20 von Hippel-Lindau (VHL) is caused by a mutation in the VHL gene and causes tumors to grow in certain parts of the body the earliest symptoms often occur in early adulthood Korbitz shares what his earliest symptoms were what managing the health condition has been like and the medication that was a complete game-changer Related: 'I Was Diagnosed With a Rare Heart Condition At 25—This Unexpected Symptom Was a Huge Red Flag' In 2007, Korbitz was 20 years old and attending college at Colorado State University when he started experiencing some unusual symptoms. “I experienced numbness in my pinky finger and it worked its way up progressively through my hand and arm. Then, my toes got numb,” he says. Korbitz also started throwing up every morning Korbitz certainly didn’t think his symptoms were the cause of anything serious “I figured that maybe it was because of hormonal changes or something in my diet,” he says After a month of the numbness and morning sickness not going away When an endoscopy didn’t show anything wrong which showed a tumor at the base of his brain stem Related: 10 Rare Autoimmune Diseases That Don't Get Enough Attention Korbitz was scheduled for emergency brain surgery to have the tumor removed which then showed that Korbitz had von Hippel-Lindau syndrome vision loss or difficulties with bowel or bladder function Related: Fitness Influencer Lexi Reed, 32, Shares 'Vulnerable' Health Update After Fighting a Rare Disease Korbitz’s emergency brain surgery was successful in removing the tumor but had devastating complications I ended up getting paralyzed on the entire right hemisphere of my body,” Korbitz says This was because the tumor was a blood vessel tumor (formed from cells that create blood vessels) and several nerves were severed during the surgery The doctors couldn’t tell Korbitz how long the paralysis would last or even if it would ever subside I just felt like I was young and life was passing me by Everyone was moving ahead with their lives and I couldn’t,” Korbitz says The doctors refused to let him leave the hospital he regained sensation in the right side of his body But due to how long he was in a hospital bed unable to move Korbitz had to learn to walk all over again because his muscles had atrophied he was told to get a CAT scan every year to identify any new forming tumors early (He notes that this protocol isn’t recommended anymore because CAT scans have a high dose of radiation.) But without health insurance Korbitz couldn’t afford to follow the doctors’ advice and it wasn’t until eight years later when he went in for a scan including a regrowth of the initial one they removed at the base of his brainstem doctors used a robotic targeted radiation system called gamma knife therapy This prevents having to dose the entire body with radiation except for eliminating the re-emerged tumor at the base of his brainstem so he underwent brain surgery again to have it removed Korbitz is able to live a full life thanks to access to the best medical care Anemia is a common side effect of belzutifan and Korbitz says is the worst symptom he experiences now including working full-time at a job he enjoys that offers health benefits that allow him access to ongoing medical care and his medication Health Advice You Can Learn FromOne major lesson that can be learned from Korbitz’s experience is to know your body and see your doctor if anything at all feels off—even if it’s as minor as numbness in your pinky Korbitz says a big lesson he learned first-hand is the importance of being your own health advocate There were times when Korbitz pushed back on what a doctor recommended seeking second opinions or listening to his gut when something didn’t feel right While it’s certainly important to take doctors’ advice seriously it’s also important to do your own research and advocate for what you feel is best Last but certainly not least, if you have a chronic health condition, Korbitz says to find your people. For him, the Von Hippel Lindau Alliance has been an incredible resource connecting him to other people with VHL and keeping him (and others with VHL) informed on the latest scientific advancements in treatment they also help people with VHL access doctors tests and medications they may not otherwise be able to afford See your doctor if something unusual is going on with your body advocate for the healthcare you want and find your community you’ll be being proactive about your health Unlock discounted publishing that highlights your organization and the peer-reviewed research and clinical experiences it produces Find out how channels are organized and operated including details on the roles and responsibilities of channel editors Offering a variety of advertising and sponsorship options for reaching influential specialists from targeted demographic splits efficient publishing and peer reviewing experience without sacrificing publication times Generate broad awareness and deliver relevant peer-reviewed clinical experiences directly to potential customers Dedicated Cranial Radiosurgery: Clinical Experience with New & Innovative SRS Technologies Real-Time Adaptive Motion Management on Helical and Robotic RT Platforms Please note that by doing so you agree to be added to our monthly email newsletter distribution list The Lindau Art Museum is hosting an exhibition titled “Christo and Jeanne-Claude - A Lifelong Journey.” Running from April 13th to October 13th, 2024, this display marks the first comprehensive museum exhibition on Christo and Jeanne-Claude in southern Germany created in collaboration with the Christo and Janne-Claude Foundation the exhibition documents the lifelong journey that led the artists to their famous large-scale temporary projects Related Article Tadao Ando Transforms Historic Scuola Grande in Venice into an Exhibition Dedicated to Artist Zeng Fanzhi You'll now receive updates based on what you follow Personalize your stream and start following your favorite authors If you have done all of this and still can't find the email We reviewed two electronic databases in the hospitals of our senior authors, searching for VHL patients with optic nerve or chiasm hemangioblastomas. Clinical data were summarized. Tumor size and growth rate were measured on contrast enhanced MRI. Comparable data were collected by literature review of all available cases in VHL patients (Pubmed, Trip, Google and Google Scholar). When optic nerve and chiasm hemangioblastomas are diagnosed, we suggest annual MRI follow-up as long as patients do not develop vision impairment. If tumors grow fast, threaten the contralateral eye, or if patients develop progressive vision deficiency; surgical resection must be considered because neurological impairment is irreversible, and resection of large tumors carries a higher risk of further visual decline. Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1334564 This article is part of the Research TopicWomen in Neuro-Oncology and Neurosurgical Oncology Vol II: 2023View all 7 articles Introduction: Optic nerve and chiasm hemangioblastomas are rare tumors occurring sporadically or in the context of von Hippel-Lindau (VHL) disease They have only been portrayed in isolated case reports and small cohorts Their natural history and therapeutic strategies are only scarcely described we retrospectively analyzed an optic nerve and chiasm hemangioblastoma series of 12 VHL patients By combining our own experience to a review of all known cases in literature we intended to create treatment recommendations for optic nerve and chiasm hemangioblastomas in VHL patients Methods: We reviewed two electronic databases in the hospitals of our senior authors searching for VHL patients with optic nerve or chiasm hemangioblastomas Tumor size and growth rate were measured on contrast enhanced MRI Comparable data were collected by literature review of all available cases in VHL patients (Pubmed 12 had optic nerve or chiasm hemangioblastomas tumors were diagnosed upon annual ophthalmoscopic/MRI screening Of 8 patients who were asymptomatic at diagnosis 7 showed absent or very slow annual progression without developing significant vision impairment One patient developed moderate vision impairment Two symptomatic patients suffered from rapid tumor growth and progressive vision impairment resulting in incomplete resection and progressive vision impairment One patient presented with acute vision field loss A watchful-waiting approach was adopted because the hemangioblastoma was ineligible for vision-sparing surgery One patient developed progressive vision impairment after watchful waiting In the literature we found 45 patient cases with 48 hemangioblastomas Discussion: When optic nerve and chiasm hemangioblastomas are diagnosed we suggest annual MRI follow-up as long as patients do not develop vision impairment or if patients develop progressive vision deficiency; surgical resection must be considered because neurological impairment is irreversible and resection of large tumors carries a higher risk of further visual decline In 1930, Verga et al. were the first to describe a case of a right optic nerve hemangioblastoma in a 57-year-old patient. It is unclear whether this patient had VHL disease. The lesion was described as a “cystic angio-reticulo-glioma” (7) optic nerve and chiasm hemangioblastomas in VHL patients have only been portrayed in isolated case reports and small patient cohorts It appears that many patients are treated with surgery leading to further visual decline or blindness No guidelines exist on the watchful waiting approach By combining our own experience to a review of the literature we intended to create the first algorithm for management of optic nerve and chiasm hemangioblastomas in VHL patients The size of the solid tumor (contrast-enhancing region) was measured in three dimensions (height divided by 2 and expressed in cubic millimeter (mm³) Tumor growth rate was measured and expressed as mm³/year Figure 1 Contrast-enhanced MRI showing an optic nerve hemangioblastoma (yellow arrow) (patient number 12) Scientific articles on VHL related optic nerve hemangioblastomas were collected by searching through Pubmed We used the following key word combinations: “optic hemangioblastoma” “optic hemangioblastoma AND von Hippel-Lindau” “optic nerve AND von Hippel-Lindau” “optic chiasm AND von Hippel-Lindau” “ophthalmology AND von Hippel-Lindau” we reviewed the reference lists of previously published articles on optic nerve hemangioblastomas in VHL patients Articles on sporadic optic nerve hemangioblastomas were excluded; as decision-making in VHL patients is different and influenced by multi-system comorbidities or the presence of bilateral tumors We focused on themes such as diagnostic approach Histopathologic description of optic nerve hemangioblastomas will not be described here because more comprehensive papers can be found on this subject Table 1 VHL related optic nerve and chiasm hemangioblastomas in our institution: summary of patient and hemangioblastoma data In our patient series, 3 hemangioblastomas were located along the left optic nerve (all 3 intraorbital and 1 with intracranial extension), and 4 hemangioblastomas were located along the right optic nerve (all 4 intracranial). There was 1 hemangioblastoma within the chiasm, and there were 4 with a retro-chiasmal location. Location of tumors is graphically illustrated in Figure 2 Mean tumor size at time of diagnosis was 11,23 mm³ (median 0,86mm³) In patients who remained completely asymptomatic during follow up (N=6) tumor size at time of diagnosis ranged from 0,38 to 50mm³ and mean growth rate was 0,89mm³/year (range 0,052 – 2,67mm³/year) tumor size ranged from 0,04 to 52,2mm³ at presentation and mean growth rate was 0,18mm³/year (range 0 – 0,46mm³/year) Mean growth rate of all tumors (both symptomatic and asymptomatic N=12) was 0,56mm³/year (range 0 – 2,67mm³/year) Figure 2 Schematic vascular supply of the optic nerve and chiasm and the relative distribution of tumors from all available cases (design by E 27 patients complained of varying ophthalmologic and/or systemic symptoms Table 2 VHL related optic nerve and chiasm hemangioblastomas reported in literature These possible scenarios are further described in the following section Figure 3 Possible clinical scenarios in patients with optic nerve hemangioblastomas Blue dots = literature patients with available progression data Of 8 asymptomatic patients followed in our clinic 6 patients remained asymptomatic during a mean watchful waiting period of 4,3 years (range 1,17–11 years) Mean tumor growth rate was 0,89 mm³/year (range 0,052 – 2,67mm³year) In literature, 6 asymptomatic patients remained asymptomatic during varying follow-up periods. Remarkably, Turkoglu et al. observed spontaneous devascularization and detachment of an optic nerve head hemangioblastoma in a 30-year-old asymptomatic female patient, after 1 year of watchful waiting (11) we discovered an intraorbital left optic nerve hemangioblastoma in a 42-year-old asymptomatic female patient During a follow-up time of 8 years without intervention the tumor grew from 0,18 to 0,23mm³ (0,006mm³/year) on MRI and the patient only needed reading glasses we discovered an intraorbital left optic nerve hemangioblastoma in a 57-year-old asymptomatic female patient the tumor grew from 0,04 to 0,56mm³ (0,08mm³/year) and visual acuity in the left eye was +4,75/-0,25 Meyerle et al. performed complete resection of an intracranial left optic nerve hemangioblastoma in a 29-year-old asymptomatic female patient. Postoperatively, the patient experienced slight visual decline in both eyes (18) Kouri et al. performed complete transsphenoidal resection of a suprachiasmal hypothalamic hemangioblastoma in a 20-year-old female patient with hormonal changes and normal vision. Her vision remained stable after surgery. Kouri et al. also reported the case of a 15-year-old asymptomatic female patient with preservation of normal vision after complete transsphenoidal resection of a left optic nerve tumor close to the chiasm (9) we followed a 50-year-old male patient with a right optic nerve hemangioblastoma close to the chiasm The patient experienced visual complaints in the beginning and became progressively blind after a watchful waiting period of 8 years Meyerle et al. reported a 60-year-old female patient with a right intraorbital optic nerve hemangioblastoma. The patient experienced progressive visual field defects in the right eye, and after a watchful waiting period of 4 years, the optic nerve had a pale fundoscopic aspect. Her vision remained stable in the sixth and seventh year, but again mildly declined during the eighth year (18) Fard et al. reported a 39-year-old male patient who experienced bilateral progressive vision impairment over 2 years; to the point of finger counting in the right eye, where he had an intraorbital optic nerve hemangioblastoma; and of light perception in the left eye, where he had an intracranial optic nerve hemangioblastoma. The patient refused therapy (12) Zywicke et al. followed a 50-year-old female patient who had an intracranial left optic nerve hemangioblastoma that extended into the optic canal. The patient experienced bilateral progressive vision impairment over a 2-year period. After the intracranial part of the tumor was resected, she experienced visual decline in the left eye, but right eye vision remained stable (14) We followed a 30-year-old male patient with progressive vision impairment in the left eye because of a left optic nerve hemangioblastoma close to the chiasm the tumor had grown from 0,56 to 6,08mm³ (0,46mm³/year) on MRI and the left optic disc had become pale on fundoscopy the patient developed a visual field defect in his other – right – eye MRI showed tumor and edema progression from the left optic hemangioblastoma to the right optic nerve In order to prevent further spread of edema the patient underwent complete surgical resection of the hemangioblastoma Bilateral visual acuity slightly decreased after surgery Visual field restriction improved in the right eye We followed a 67-year-old male patient with a large chiasmal hemangioblastoma that extended to both optic nerves The patient was almost blind in his right eye but nevertheless he was operated because of progressive visual field loss in the left eye Visual status remained stable after complete left-sided and incomplete right-sided resection of the tumor In 1995, Balcer et al. reported a 21-year-old female patient with an intracranial left optic nerve hemangioblastoma, who experienced bilateral progressive slight visual decline over 2 years. After total excision of the left optic nerve tumor, she experienced bilateral mild visual improvement (25) Rubio et al. reported a 43-year-old female patient with an intraorbital right optic nerve hemangioblastoma that extended into the optic canal. After 4 years of slight visual decline in the right eye, she experienced sudden blindness of the right eye. The right optic nerve was completely resected, resulting in blindness of the right eye (27) McGrath et al. published a case of a 25-year-old asymptomatic female patient with a right intraorbital optic nerve tumor. For 3 years she remained clinically and radiographically stable, until rapid visual decline developed over a six-month period, due to bilateral optic tract edema that could be seen on MRI. The tumor was completely resected and postoperatively the patient was only able to discern light in the right eye (35) Meyerle et al. reported a 54-year-old male asymptomatic patient with a left intracranial optic nerve hemangioblastoma extending to the optic canal, who remained stable for 8 years, until his vision suddenly declined to counting fingers only. As in McGrath’s case, bilateral white tract edema was seen on MRI. The tumor was completely resected, resulting in slight visual improvement in the left eye and sparing of vision in the right eye (18) Kanno et al. wrote a case report on a 36-year-old female patient, who had rapid visual decline until the left eye could only perceive light and the optic disc became pale on fundoscopy. A large left intraorbital optic nerve hemangioblastoma was discovered. The patient became completely blind after stereotactic radiosurgery (10) In 1992, Ginzburg et al. reported a 44-year-old male patient who experienced severe bilateral vision impairment over an 8-month period, due to bilateral optic nerve hemangioblastomas. Partial tumor resection in the left eye led to blindness, and total tumor resection in the right eye led to being able to distinguish objects (28) Prabhu et al. described a 32-year-old male patient, with a right intracranial optic nerve hemangioblastoma that caused visual decline in the right eye over an 8-month period. Vision remained stable after complete tumor resection (15) Baggenstos et al. reported a 62-year-old male patient with an intracranial left optic nerve hemangioblastoma with bilateral white tract edema, who experienced progressive vision impairment in the right eye and sudden vision impairment in the left eye. After complete resection of the tumor, edema resolved and left eye vision improved (16) Meyerle et al. presented a 15-year-old female patient who had no visual complaints; however, there was slight vision loss in the left eye on measuring. She had an intracranial left optic nerve hemangioblastoma that radiologically grew over a 6-month period and then started to compress the chiasm. The tumor was completely resected, and after 9 years, the patient had a small quadranopsia but regained visual acuity (18) A 56-year-old patient in our clinic experienced an acute visual field defect in the right eye. Fundoscopy was normal and MRI showed a large right intraorbital optic nerve hemangioblastoma without surrounding edema (Figure 4 Corticosteroids did not improve his symptoms Because surgical resection was unfeasible and was anticipated to lead to total blindness of the right eye the patient was not operated – to cherish a couple more “good” years Surgery will be planned as soon as peritumoral edema develops and threatens the contralateral eye Tumor volume has now remained stable for 4 years Figure 4 Axial contrast enhanced T1 MRI A 56-year-old male VHL patient followed in our clinic with a right optic nerve hemangioblastoma The patient experienced acute visual field defects in the right eye MRI showed a large right intraorbital optic nerve hemangioblastoma without edema (yellow arrow) Corticosteroids were not effective for reducing symptoms tumor length 31mm and width 6.7mm (= growth); note progression towards optic chiasm but shorter image acquisition time after contrast administration D): longer image acquisition time after contrast administration there is growth compared to (A) Note peritumoral contrast leakage along optic nerve tract In some case reports, there is no focus on symptomatology or it is not mentioned (Kerr et al. (24), Hotta et al. (29), Miyagami et al. (26), Tanaka et al. (30), Uehara and Ichinomiya (32) and Verga et al. (7), Vásquez Montoya et al. (8) All other reported patients were symptomatic at time of diagnosis The time interval between initiation of symptoms and the seeking of medical attention ranged from 24 hours to 7 years Bilateral papilledema is caused by either bilateral optic hemangioblastomas or by edema spread through the chiasm and in the absence of visual improvement after photocoagulation previous enucleation of the eye due to large retinal lesions does not exclude the development of a hemangioblastoma along the course of the optic nerve which can potentially harm the other eye by edematous spread As described in two cases, we recommend testing of pituitary function before surgery if the optic nerve hemangioblastomas is in close contact to the pituitary stalk or gland (9, 25) Stefani and colleagues reported normal spinal fluid analysis in one patient. We found no other data on spinal fluid analysis in the literature (33) it may be tricky to distinguish hemangioblastomas from intraorbital fat on contrast enhanced T1-weighted MRI or Fluid Attenuated Inversion Recovery (FLAIR) Short Tau Inversion Recovery (STIR) or fat suppression sequences may be used Large peritumoral cysts are less often encountered than with cerebellar hemangioblastomas, which can also be found in VHL patients (20, 22) In cases where high perioperative bleeding is expected preoperative embolization of major supplying vessels may be considered but this is usually not feasible because of shared blood supply with the optic nerve The typical growth patterns of the abovementioned other tumors can be used for differentiation with optic nerve hemangioblastomas. Low-grade meningiomas grow slowly while gliomas and especially brain metastasis show rapid progression. It is however frustrating that hemangioblastomas are known for their capricious growth, which may be linear, exponential, saltatory or very rapid after years of stability (39) Meningiomas can be calcified on CT (22). Optic nerve hemangioblastomas may cause expansion of the bony optic canal on coronal CT. This expansion is benign and usually non-erosive, while brain metastases may cause wide bony destruction (17) Vascular flow voids can be seen in hemangioblastomas with thick vessels, but flow voids are absent in gliomas and can only rarely be seen in large meningiomas (18) In meningiomas, a contrast enhancing dural tail may be seen on coronal MRI images, while hemangioblastomas and brain metastases are located within the nerve (12, 17) if the patient is not known with VHL disease the diagnosis of an optic nerve hemangioblastoma warrants screening for VHL disease No guidelines exist on the management on optic nerve hemangioblastomas. The authors of the VHL handbook recognize that optic nerve-sparing surgery can be very challenging; thus, they suggest not to operate on asymptomatic optic nerve hemangioblastomas, without further specification on the broad range of possible clinical scenarios (40) By combining our own experience to an in-depth review of all available cases in literature The surgical indications we found in the literature included: (1) young age, (2) radiographical growth, (3) postoperative vision loss expected to be minimal, (4) to prevent symptoms in an asymptomatic patient, and (5) to preserve contralateral vision (18). Some authors have stated that watchful waiting always results in vision impairment (21); however based on our own success with the watchful waiting approach We only recommend considering surgery if patients develop vision impairment or if there is contralateral spread of either tumor or edema Rapid visual decline and bilateral symptoms due to peritumoral edema are major indications for urgent surgery (18, 35, 41). Edema is an early indicator of impending vision disturbance (16) Most authors recommend complete excision of the optic nerve if vision is already lost and the patient has severe or painful proptosis (5, 35). Incomplete resection of such hemangioblastomas usually leads to recurrence and accelerated growth (22, 42–44). Postoperatively, regression of proptosis may take some months (5) contralateral eye function and prognosis of other VHL-associated tumors are also major influencers on surgical decision making A suggested follow-up and treatment protocol is graphically summarized in Figure 5 Figure 5 Suggested protocol for treatment and follow-up of VHL optic nerve hemangioblastomas some neurosurgeons prefer not to disturb canalicular anatomy because of the risk of disrupting the annulus of Zinn where the four rectus muscles originate The transsphenoidal access may be valuable for growing children with normal pituitary function because it avoids frontotemporal lobe retraction and separation of the sylvian fissure. Depending on the experience of the surgeon, transsphenoidal surgery is less likely to cause morbidity and mortality. Nevertheless, an large sella is required for broad exposure because internal carotid artery injury is an eminent threat (9) we suggest to first fenestrate the cyst in order to widen the surgical field and facilitate dissection of the nodule Optic nerve hemangioblastomas may bleed profoundly, leading to postoperative visual decline. Therefore, we do not recommend performing a biopsy or incision unless the tumor is totally resected (28) Some optic hemangioblastomas may be difficult to access because of their central location in the optic nerve or involvement of the surrounding structures such as the internal carotid artery together with the imminent threat of edema makes this narrow alley a worthy adversary during surgery Other reported surgical complications are eye motility disturbance (5) and transient diabetes insipidus due to hypophyseal traction (23). Transsphenoidal approaches may be complicated by bleeding, cerebrospinal fluid rhinorrhea and meningitis (9) Contrast-enhanced MRI can be used for follow-up of tumor volume and peritumoral edema. According to our own experience, the typical leaky vasculature of hemangioblastomas may cause contrast extravasation and therefore an overestimation of tumor volume on MRI. We suggest standardizing the time interval between intravenous gadolinium administration and MRI image acquisition, to minimize the effect of this overestimation on tumor volume comparison (Figure 4) chances are high that radiosurgery will not influence tumor volume The use of high dose intravenous corticosteroids has been described in several case reports, and often because optic neuritis was suspected at initial presentation. Subjective improvement of vision has been described by patients; however, we found no reports on objective improvement as measured by technical examination (12, 16, 35) The administration of corticosteroids seems reasonable for temporary relief of vasogenic edema surrounding hemangioblastomas For non-optic nerve VHL related hemangioblastomas surgical resection remains the gold standard Pharmacological trials have recently been focusing on the inhibition of Hypoxia Response Elements and their respective receptors especially vascular endothelial growth factor and receptor (VEGF There have been pharmacological triumphs in the treatment of VHL clear cell carcinomas for example with the HIF2α inhibitor belzutifan Belzutifan also seems to be efficacious for hemangioblastoma tumor control; however intratumoral hemorrhages have been described necessitating the development of other therapies The effect on optic nerve hemangioblastomas has not been investigated and this will remain challenging given their rarity If hemangioblastomas of the optic nerve and chiasm are diagnosed we suggest annual routine follow-up as long as patients do not develop vision deficiency If tumors grow fast and/or patients develop vision impairment we recommend resection and resection of large tumors carries a higher risk of further vision decline we recommend surgical resection if MRI shows imminent edema or tumor spread to the chiasm or contralateral optic nerve Edema can be present before vision impairment becomes clinically evident we recommend waiting until full blindness (because vision sparing surgery is unlikely at this stage) unless the contralateral eye is threatened by spreading edema All relevant data is contained within the article: the original contributions presented in the study are included in the article/supplementary material further inquiries can be directed to the corresponding author/s The studies involving humans were approved by Universitair Ziekenhuis Brussel ethics committee The studies were conducted in accordance with the local legislation and institutional requirements Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements The author(s) declare that no financial support was received for the research The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher Primary tumours of the optic nerve and its sheath PubMed Abstract | CrossRef Full Text | Google Scholar Surveillance in von Hippel-Lindau disease (vHL) doi: 10.1111/j.1399-0004.2009.01281.x PubMed Abstract | CrossRef Full Text | Google Scholar Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease and retinal function and structure in von Hippel-Lindau disease Compressive and infiltrative optic neuropathies Walsh and hoyt's clinical neuro-ophthalmology Philadelphia: Lippincott Williams & Wilkins (2005) Google Scholar Angio-reticolo-glioma cistico del nervo ottico Google Scholar Optic nerve haemangioblastoma in association with von Hippel-Lindau syndrome: case report and literature review Resection of suprasellar tumors by using a modified transsphenoidal approach VHL-associated optic nerve hemangioblastoma treated with stereotactic radiosurgery Spontaneous devascularization and detachment of optic nerve hemangioblastoma in a patient with von hippel-lindau disease doi: 10.1001/jamaophthalmol.2016.1119 Bilateral optic nerve head angiomas and retrobulbar haemangioblastomas in von hippel-lindau disease Hemangioblastoma of the optic nerve producing bilateral optic tract edema in a patient with von Hippel-Lindau disease Optic nerve hemangioblastoma: a case report PubMed Abstract | CrossRef Full Text | Google Scholar Optic nerve haemangioblastoma mimicking a planum sphenoidale meningioma Progressive peritumoral edema defining the optic fibers and resulting in reversible visual loss PubMed Abstract | CrossRef Full Text | Google Scholar Clinical course of retrobulbar hemangioblastomas in von Hippel-Lindau disease Retrobulbar hemangioblastomas in von hippel-lindau disease: clinical course and management Hemangioblastoma of the optic nerve–case report [An optic nerve tumor in von Hippel-Lindau disease Case 5: An optic nerve mass in von Hippel-Lindau disease Google Scholar Successful surgical removal of an asymptomatic optic nerve hemangioblastoma in von Hippel-Lindau disease Hemangioblastoma of the optic nerve: case report doi: 10.1227/00006123-199503000-00017 von Hippel-Lindau disease manifesting as a chiasmal syndrome [The two familial occurrence of von Hippel-Lindau disease] PubMed Abstract | Google Scholar Diagnosis of von Hippel-Lindau disease in a patient with blindness resulting from bilateral optic nerve hemangioblastomas A case of intraorbital hemangioblastoma of the optic nerve Google Scholar Hemangioblastoma of the optic nerve: radiographic and pathologic features PubMed Abstract | Google Scholar A case of intraorbital optic nerve hemangioblastoma associated with von Hippel's disease Google Scholar PubMed Abstract | CrossRef Full Text | Google Scholar Microanatomy of the blood supply to the optic nerve PubMed Abstract | CrossRef Full Text | Google Scholar Optic nerve haemangioblastoma: signs of chronicity PubMed Abstract | CrossRef Full Text | Google Scholar PubMed Abstract | CrossRef Full Text | Google Scholar Intraorbital optic nerve hemangioblastoma with von Hippel-Lindau disease Hemangioblastomas and neurogenic polyglobulia The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease In: A reference handbook for people with von Hippel-Lindau Google Scholar Case report with study by light and electron microscopy PubMed Abstract | CrossRef Full Text | Google Scholar PubMed Abstract | CrossRef Full Text | Google Scholar Cerebellar hemangioma (hemangioblastoma); a clinicopathological review of 40 cases PubMed Abstract | CrossRef Full Text | Google Scholar Optic nerve hemangioblastomas?A review of visual outcomes doi: 10.5137/1019-5149.JTN.16680-15.1 Haemangioblastoma with multiple dural arterial supply Origin and intra-cranial and intra-canalicular course PubMed Abstract | CrossRef Full Text | Google Scholar Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas doi: 10.1227/01.NEU.0000348015.51685.D2 Andreescu CE and Gläsker S (2024) Optic nerve and chiasm hemangioblastomas in von Hippel-Lindau disease: report of 12 cases and review of the literature Received: 07 November 2023; Accepted: 19 June 2024;Published: 09 July 2024 Copyright © 2024 Vergauwen, Klingler, Krüger, Steiert, Kuijpers, Rosahl, Vanbinst, Andreescu and Gläsker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) distribution or reproduction in other forums is permitted provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited in accordance with accepted academic practice distribution or reproduction is permitted which does not comply with these terms *Correspondence: Evelynn Vergauwen, ZXZlbHlubi12QGhvdG1haWwuY29t Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. 94% of researchers rate our articles as excellent or goodLearn more about the work of our research integrity team to safeguard the quality of each article we publish. Mike Pols (left) with Nobel laureate John Mather Martine Schut (second from left) with other participants Sanne Bloot (second from left) met Nobel laureate Gerardus 't Hooft (centre) Next Tell us a bit about yourself and your scientific interests.Sanne: I'm an astronomer, and my PhD involves looking for stars and planets with radio telescopes. We can study stars and exoplanets with a large number of wavelengths, but I’m most interested in working with radio waves because they can give us information about the magnetic fields of stars and the planets orbiting them. Mike: My PhD project involves conducting material simulations of a new material for optoelectronic applications called ‘metal halide perovskites’. With the simulations, I’m attempting to understand the dynamics and disintegration of the material at the atomic scale. Martine: I’m mainly interested in quantum physics, specifically in such phenomena as entanglement and superposition. I’m trying to work out how we can use these quantum phenomena for improved sensors, for example to detect very weak gravitational signals. Sanne: For me, that was Saul Perlmutter. He gave a lecture on scientific thinking, and he talked about the course he teaches on that subject. That got me thinking about ways I can convince people around me to approach the world with a scientific attitude. Mike: A lot of what the laureates told us was impressive, but for me the enthusiastic way Steven Chu talked about his scientific and social career during the Science Walk was particularly inspiring. Martine: Even though he doesn't work in the same field as me, I think the Open Exchange with Steven Chu impressed me the most. His career is really inspiring. He talked openly about how and why he took on a government job, and how he’s managed to change fields so often. His message was actually very simple: ‘follow your dreams’, but he delivered it in a fun way and he also gave a lot of room for societal issues during the discussions. Mike: During the week I was there, I really enjoyed connecting with the other young researchers and the Nobel laureates. Hearing all those stories and about all the different backgrounds has really motivated me to follow the advice and to go where your heart tells you in the world of science. Martine: There were a whole lot of special moments: I got to give a presentation to a large audience, I had lunch with Alain Aspect, and I had breakfast at a panel discussion with Nobel laureates. But what I'll remember most is the enthusiasm and level-headedness of both the Nobel laureates and the other young researchers who attended. Everyone was friendly, open to discussion and enthusiastic about their own research. That was really engaging and motivating. Submit nominations:Is opening 16 August 2025Lindau Nobel Laureate MeetingsDuring the Lindau Nobel Laureate Meetings, talented young researchers have the opportunity to meet peers from almost 100 countries and to talk to Nobel laureates. Traveling to Europe to spend a week in the company of Nobel Prize winners sounds like a dream for any early-career scientist. It certainly did for Dr. Sarah Martell, who couldn’t believe it when she was selected to attend the 74th Lindau Nobel Laureate Meeting happening this summer and then I laughed because I thought I read it wrong,” recounts Dr “I couldn’t really believe it because it just seems like such a wild opportunity I was quite shocked to hear that I was accepted Dr. Martell, a Dal alum (PhD’23) and former postdoctoral fellow in Dr. Mita Dasog’s research group who recently started a new position as the lab’s program manager will join 600 young scientist peers from around the world and 35 Nobel Prize winners in Lindau Germany from June 29-July 4 for a week of workshops The exclusive gatherings have been held annually in the southern German town since 1951 and focus on one of three natural science Nobel Prize disciplines: physiology/medicine “Sarah is an emerging leader in materials science with a remarkable ability to translate fundamental research into real-world applications,” says Dr Martell’s candidacy through the Global Young Academy one of the conference’s nominating institutions Sarah is deeply committed to advancing science literacy and promoting diversity and perspective will undoubtedly enrich the dialogue among emerging and established scientific leaders.” “I’m really excited for the more philosophical discussions about our role as scientists in society today especially with so much misinformation out there,” they say They are also looking forward to making hundreds of new connections admitting to browsing LinkedIn in search of updates from others announcing their participation where she recently took on the role of program manager While there isn’t a specific Nobel Laureate who Dr. Martell is hoping to cross paths with (“All these people are rockstars,” she says), she plans to seek out Ada E. Yonath and Frances H. Arnold — the only women in an otherwise male-dominated group of attending Laureates “Even though they’re not really in my direct field I want to hear more about their experiences,” she says Before an international audience at the Falling Walls Science Summit she pitched a new method of on-demand hydrogen generation in which synthesized porous silicon nanoparticles react with water While nothing that stressful is in store this time she hopes to be selected to present her work at one of the week’s “Next Gen Science” sessions soaking up as much knowledge as possible in the presence of so many great minds “It’s going to be a wild experience that I’m really excited for.” We use cookies and other technologies to better understand a visitor's experience and to help improve our websites. By continuing to use the website, you consent to Middlebury's use of cookies and other technologies as outlined in our Privacy Policy Elizabeth joined Middlebury in the summer of 2021 After an eclectic career path that included working as a carpenter in Antarctica managing marketing for a green architecture firm and helping to restore the only surviving prototype of Buckminster Fuller’s Dymaxion House she found her calling in higher education as a major- and planned gifts officer At Middlebury she works with alumni and families in Asia Elizabeth received her BA from Kalamazoo College where she majored in chemistry and art/art history completed an internship at the Brooklyn Museum and played change ringing bells in the chapel tower She resides in Michigan with her husband Jeff and senior rescue poodle Elizabeth can be found tackling various home repair projects and studying Japanese.  Eleven of Australia’s brightest early-career scientists have attended the 73rd Lindau Nobel Laureate Meeting is a highly prestigious annual gathering of Nobel Laureates and approximately 600 young scientists from around the world It provides a unique opportunity for the young scientists to share their research the Australian delegates held their own at the event Grace Tabi from the Australian National University (ANU) presented her research on perovskite solar cells gave a presentation on turbulent fluid dynamics in Antarctic ice shelf melt predictions Posting about their experiences via Academy communication channels, the delegates shared in their final X (formerly Twitter) thread: “Reflecting on the experience We carry with us new ideas and perspectives empowered by the shared knowledge of Nobel Laureates and fellow young scientists we will use these insights to shape a brighter future!” the Academy organised a research innovation tour in Berlin in the lead-up to the Lindau meeting The tour enabled the young scientists to visit a range of prestigious research institutes connected to their fields of studies at the Australian Embassy in Berlin and learnt about the role of science in Australia and Germany’s bilateral relationship Dr Barnali Das of CSIRO said the Lindau meeting filled her with a new sense of responsibility to society and strengthened her love for physics The Australian delegation was led by astrophysicist and Academy Fellow Professor Elaine Sadler and supported by optical physicist and Academy Fellow Professor Hans Bachor Participation in the Lindau Nobel Laureate Meetings is proudly supported by the Science and Industry Endowment Fund (SIEF) and administered by the Australian Academy of Science Next year’s 74th Lindau Nobel Laureate Meeting which is dedicated to the discipline of chemistry Applications for the 74th Lindau Nobel Laureate Meeting will open in August 2024 Chloé Nibourel and Leopoldo Lazcano from the Swedish Institute for Social Research (SOFI) have been selected to participate in the 8th Lindau Nobel Meeting in Economic Sciences The Lindau Meetings bring together outstanding young scientists from around the world to engage in dialogue and exchange ideas with Nobel Laureates. Chloé Nibourel and Leopoldo Lazcano are two of only 250 promising young economists worldwide invited to this prestigious event ”Honored to be part of the Lindau Meetings Having the opportunity to hear Nobel Laureates' perspectives on the most pressing challenges and connect with the next generation of economists What an incredible program,” said Chloé Nibourel Nibourel specialize in political and public economics using data and econometric methods to better understand current trends in democratic systems Her research primarily focuses on political polarization and its impact on elections and public policy "Getting the chance to meet 20 Nobel Prize winners from my own field in just one week is unbelievable and I believe it will be a very enlightening experience,” said Leopoldo Lazcano His doctoral research focuses on labor economics and social policies will focus on cutting-edge topics in economic sciences facilitating interactions between the next generation of economic researchers and Nobel Laureates The University of California today (April 8) announced its fifth class of UC President’s Lindau Nobel Laureate Meetings Fellows, 27 highly accomplished young scientists awarded the opportunity to join Nobel laureates from around the globe at the 2024 Lindau Nobel Laureate Meeting in Germany “We are thrilled to provide some of the University’s most promising scientists the opportunity to attend this one-of-a-kind scholarly summit,” said UC President Michael V are foundational to the University of California’s mission of teaching is funded by UC Investments and UC’s national laboratories to allow a select group of UC doctoral and postdoctoral students to attend the annual event candidates and postdocs have taken part in the highly competitive program which brings together different generations the UC President’s Lindau Nobel Laureate Meetings Fellows now number 100 from the 10 UC campuses and 30 from the UC-affiliated national laboratories I had the opportunity to attend the meetings as a guest and was quickly absorbed in a feast of learning that never failed to spark ideas and new paths to follow,” said UC Chief Investment Officer Jagdeep Singh Bachher the Nobel laureates are generous with this time and wisdom “We are honored to once again support another remarkable cohort of young researchers from our national laboratories and help support their participation at this rewarding event,” said June Yu interim vice president for National Laboratories “This year’s Lindau meeting offers the fellows a unique opportunity to interact and connect with other outstanding early-career scientists and accomplished physicists from around the world.” The diverse group of UC fellows were nominated by UC faculty and chosen after submitting an essay an evaluation of their research accomplishments and approval by the Lindau meetings organization in Germany A UC work group that included two Nobel Prize laureates narrowed down the candidates This year’s fellows from UC campuses for the physics meetings are: The fellows representing the national laboratories are as follows: The UC President’s Lindau Nobel Laureate Meetings Fellowship is open to students and postdocs from all 10 UC campuses as well as the three UC-affiliated National Laboratories The University of California opened its doors in 1869 with just 10 faculty members and 40 students the UC system has more than 295,000 students and 265,000 faculty and staff with 2.0 million alumni living and working around the world the Michigan Ross BBA Program is one of the best undergraduate business program in the world Explore what makes our inclusive community of learners so unique you gain more than just a first-class business education inclusive community enriches your experience and sets you up with a lifetime network of friends across the globe The work of Michigan Ross faculty influences the world’s largest companies and global economies Every day we’re creating real-world solutions for the most pressing challenges in our world.  dedicated location in downtown Los Angeles provides greater access to a world-class business education for students and professionals on the West Coast.  Michigan Ross is driving the real-world impact of AI through research and policy to build a better world through business Benjamin Lindau, BBA ‘21, balances two high-level career pursuits: He’s an analyst at the Related Companies office in Chicago and a member of the United States Para Men’s National Soccer Team he’s represented his country all over the world and even won a bronze medal at the 2019 ParaPan Am Games in Lima while a student at the Ross School of Business.  Currently, Lindau works more than 10 hour days at Related Companies and then trains for multiple hours in the evening. Then there’s his commitments to Team USA and Edgewater Castle FC a semi-professional soccer club from the northside of Chicago his professional and soccer careers are an all-consuming undertaking but Lindau can’t imagine a life without his dual ambitions “I would really struggle to perform as an athlete if I didn't feel like I could chase my professional dreams,” Lindau said “I feel like the luckiest person in the world To be a top-level athlete and professional are the two career paths I really wanted in my life.” Lindau had dreams of playing soccer and starting his own business he suffered a stroke that paralized the left side of his body “It was a blessing in disguise that I had gotten interested in soccer right before the stroke,” Lindau said “It gave me a huge motivation to follow through with the physical therapy and rehab so that I could get back to playing.” Lindau relearned how to perform all of his usual day-to-day tasks His opportunity to play professional soccer came in high school after reading a social media post about the U.S. Men’s Soccer team involving the 2016 Summer Paralympics in Rio de Janeiro Lindau reached out to the coach and was invited to join Team USA shortly after the games were complete he started applying to business school and was accepted into the BBA program at Michigan Ross becoming a third-generation Michigan legacy A highlight of Lindau’s development at Michigan Ross came from the group work assigned by many of his professors he served as the financial lead on a project his role was to develop and use his soft skills or to think outside of the box to come up with creative solutions It taught him to be flexible and to master a variety of business-related tasks both of which are invaluable in a professional setting “One thing I learned about myself is that I'm really comfortable being able to step back and allow myself to fall into whatever role needs to be occupied,” said Lindau The lessons in adaptability that Lindau took from Michigan Ross make him an ideal fit as an analyst at Related Companies where each work day looks different than the last Lindau develops financial models and manages projects to evaluate potential acquisitions and in-progress Chicago developments he’s out in the field touring prospective properties and meeting with investors he’s adjusting and adding figures in Excel spreadsheets Lindau developed invaluable connections at Michigan Ross that continue to benefit him today “He was head of the Michigan Real Estate Club,” Lindau said “I took his class and it really lit the fire for real estate within me.” Allen helped Lindau land his position at Related Companies and the two are still working on a few projects together regarding the Equitable Ann Arbor Land Trust a nonprofit Allen recently launched to develop affordable housing in the city The pair frequently discuss Allen’s goals for the trust and along with others at Related Companies Lindau advises Allen on how to best accomplish those goals That's the kind of story that means a lot to me — that a professor was willing to go out of his way to help me But there were a number of professors throughout my time at the business school who were willing to sit down with me and help me navigate the business canvas Lindau honed the ability to manage a rigorous workload with the demands of competing in international soccer competitions He trained full-time while studying at Ross and fortunately many of his professors offered the flexibility he needed to maintain his commitment to Team USA while pursuing his degree “A number of Ross professors definitely supported my athletic endeavors and I'm really appreciative of that,” Lindau said “It meant a lot to me that there were people who were willing to back me up on that.” Lindau is thankful that, like his professors, Related Companies is supportive of his soccer career. In May, he competed with the U.S. Para Men’s Team in the International Federation of CP Football World Cup in Barcelona and next year he plans to travel to Santiago for the 2023 ParaPan Am Game — only this time he’s hoping for gold Lindau hasn’t given up his dream of becoming an entrepreneur and starting his own business but he also sees the potential for growth and a long career at Related Companies he is confident he’ll be prepared for the challenges that lie ahead Ross students are in a unique position to face life after college in a way that other people really are not but it's the fact of the matter that Ross simply opens doors that otherwise would not be available to you Then it's up to you to walk through those doors +1 (734) 615-5002  Building Hours © 2024 The Regents of the University of Michigan Kochi: A post-graduate student from Kerala’s Kochi is all set to interact with a host of Nobel laureates a fifth-year Integrated MSc Chemistry student from the Department of Applied Chemistry at Cochin University of Science and Technology (CUSAT) is among the group of young scientists representing India at the 74th edition of the prestigious Lindau Nobel Laureate Meeting to be held in Lindau The 74th edition of the coveted academic meeting will focus on Chemistry More than 30 Nobel Laureates in the discipline will attend the event with about 600 young scientists from around the world Niranjana said she was lucky to have such an opportunity at a young age Lindau meetings allow the delegates to have one-on-one meetings with Nobel laureates I’m looking forward to meeting some of the recent laureates who won the Nobel prize for their achievements in organocatalysis and click chemistry in which I’m interested,” Niranjana told Onmanorama Niranjana applied for the programme after hearing about it from a faculty member The Union Government’s Department of Science and Technology an academic partner of Lindau Nobel Laureate Meetings The Lindau Meetings selection panel made the final selection Candidates’ research aptitude was a key criterion for the selection Niranjana believes the nature of her programme in CUSAT She has already published research papers in academic journals a research student in the Department of Physics a retired government employee turned lawyer Niranjana plans to do research in Chemistry after her postgraduate studies as well as pursue her interest in classical dance She did her schooling in Bhavan's Vidya Mandir the Lindau Nobel Laureate Meetings are held annually with the theme alternating between Physics An interdisciplinary meeting takes place every five years while the Lindau Nobel Meeting in Economic Sciences is held every three years the Lindau Nobel Laureate Meetings provide a globally recognised forum for exchange between Nobel Laureates and young scientists They inspire scientific generations and build sustainable networks of young scientists worldwide Live Cast Christine Louise Lindau (nee Lawonn) was born on August 24 but was blessed with her loving stepmother Christine attended Concordia Teacher’s College in Seward NE and earned her Bachelor of Science in Education Christine was a Lutheran schoolteacher in Texas and Michigan Robert and Christine were married in Frankenmuth Robert was ordained as a Lutheran pastor in 1981 and Christine faithfully served as a pastor’s wife for the next 32 years Christine was the model of a Christian woman She embodied and lived every one of the Fruits of the Spirit and Timothy Howard Lindau (Bridget); her six grandchildren and Heidi Aurich (Arlie) and her brother-in-law Richard Lindau Christine was preceded in death by her parents A celebration of Christine’s eternal life with her Lord and Savior will be held Saturday at Zion Lutheran Church   A visitation with family and friends will be held prior to the service Memorials in Christine’s name can be made to the Scholarship Fund for Concordia Lutheran High School NE 68116 or the Methodist Hospital Foundation The Lindau family wishes to convey its gratitude for the loving and compassionate care of the whole team at VNA Hospice It’s been a long time since I’ve seen any of y’all but she was an amazing lady May God wrap His arms around you during this difficult time She is my teaching role model and a great model to follow as a pastor’s wife Yvonne and I send our Christian love and sympathy to Rev Rob…and all the family members of your beloved wife in Council Bluffs and I will notify her of Christine’s passing We thank God for His gift to you of your loved one Dear Bob and family-I was so surprised to hear in chuch that Chris had passed away So many memories of when you lived in Richville and we would go to plays at Pit and Balcony fondue with Jack and Gerry and you came to visit us in Virginia when Don worked for NASA I remember all the bible studies we had at the parsonage in New Fane Those memories of you and your family at St I just learned of Chris’ heavenly journey While it’s difficult to live on this earth without our loved ones thinking of them in heaven enjoying total happiness brings joy I had the honor of knowing Chris in high school at LHS in Denver Heafey-Hoffmann-Dworak-Cutler Mortuaries © 2024 All Rights Reserved Terms of Use and Privacy Policy America is disconnected from veterans and military families my husband and I sipped chilled Aperol spritzes in the German town of Lindau regal Bavarian lion sculpture that welcomes travelers into the harbor to the rolling hills of Austria to the southeast and Switzerland to the west This moment of relaxation felt deserved after a long and bumpy permanent change of station (PCS) that took us from Washington to Stuttgart in the middle of a raging pandemic Lindau was already on our list of German cities to explore when we arrived in early July But we never considered that our first visit would be for a command-sponsored marriage retreat The sun sets over the Lindau harbor on Lake Constance in Germany This latest PCS is the third I’ve experienced with my husband It was by far the most complicated and stressful—our first move overseas with very different career paths ahead for us both as my partner branched out into a career-broadening operational assignment salaried reporting gig to try my luck in the fearsome world of freelance and the time I spent preparing them for our two flights and stressing about their well-being en route resulted in more than a few premature gray hairs we spent four years in Washington—the center of all the action a prime spot for both of us to hone our nascent journalism and acquisition officer careers Four years in one assignment can feel interminable; we started getting antsy to move at around the 18-month mark networking scene became exhausting to uphold we went through more and more late nights and long work trips and had less time to bond and keep growing together Stuttgart was our number one pick for the next move: a cosmopolitan city with easy access to the continent by plane and when the assignment finally came through a little after the 2020 new year we were ecstatic—and more than a little relieved Our mindset instantly changed to: As soon as we get to Germany all the stress we’ve been feeling from these jobs We just have to get through these last few months Air Force 353rd Special Operations Group Airmen and their spouses enjoy a date night during the Preservation of the Force and Families-hosted Marriage Care retreat at Ie Island Then Covid-19 overtook the world in spring 2020 Of all the new adventures I envisioned during our time in Europe our first-ever marriage retreat didn’t make the list and DIY towers made out of marshmallows and straws meant to encourage communication will help us power our marriage long after we end this assignment This experience started with an email from my husband’s new command encouraging couples under Special Operations Command-Africa (SOCAF) to spend a weekend in Lindau and materials were all provided for a retreat in a picturesque lakeside village with about 12 hours of workshops followed by time to explore the town at our leisure The prospect of getting touchy-feely with a crew of unfamiliar coworkers from the special-ops world didn’t thrill my partner and despite the rough patch we had gone through together in D.C. we didn’t feel like a couple that really needed any sort of marriage counseling But the offering was too appealing to pass up As we walked into the elegant 19th-century Hotel Bayerischer Hof I wondered how many operators—a community known more for their acumen behind enemy lines than for their emotional vulnerability—would willingly open up about even the smallest of marriage struggles knowing that the friendly folks beside them might include a future boss or deployment buddy we all arrived ready to take something constructive away from the weekend we spanned a wide range of ages and experiences came in with a cautious curiosity: willing to engage Others had clearly been on many retreats in the past and gamely ran through the exercises and discussions with confidence and experience Air Force 353rd Special Operations Group Airmen and their spouses practice positive communication skills during the Marriage Care retreat’s second classroom session brought an unassuming air to the resiliency training and greeted new and returning couples like old friends Smith readily offered up multiple examples of where he fell short in his own marriage We went over the five common love languages as conceptualized in Gary Chapman’s 1992 bestseller The 5 Love Languages a common book used in marriage and relationship counseling suggested that every individual prefers to receive love in one of five ways (Hint: You probably have a different one from your partner.)  I was pleasantly surprised by the time dedicated to topics like meal planning and deep breathing exercises While the workshop skewed more toward ice-breaking activities and sanguine discussions about the ups and downs of partnership there were a handful of more emotional moments all handled by Smith and his aides with respect Smith told us that he tries to shake up each retreat with new tools and recommendations an officer working as a physical trainer at SOCAF gifted each pair with a foam roller set then demonstrated stretches for relaxing and resetting after a stressful day These stretches can’t completely replace the comfort that comes with talking through a work problem together But it does help us feel like we’re doing something about it able to share only that a work project isn’t moving fast enough or got complicated somehow it’s obvious that the stress and tension we experienced in D.C did not magically evaporate as soon as our plane entered European airspace Old work challenges just evolve into new ones but we’re both spending much more time in it That has forced us to face long-simmering concerns or gripes and really come to terms with them as a couple as part of a military-sponsored marriage retreat in the fall of 2020 the stresses that we feel now will not magically dissipate once Covid is under control we’ve employed the tips and tricks that we learned in Lindau to help our marriage run more smoothly—more synchronized We military families are used to having amenities provided and decided for us: where we move next But warfighters may not feel comfortable sharing their vulnerabilities with the same people who sign off on their performance reports or who may someday ride shotgun with them on a patrol through Niger along with other marriage resiliency resources offered by the DOD are “one of the strongest tools a commander can use to strengthen his team’s relationships,” Smith While it may be tradition for military members to leave their personal lives at home using resources tailor-made for our unique existence can provide real benefits Smith likens these getaways to routine car maintenance You may think your marriage is as fine-tuned as a Ferrari but even Italian sports cars need to get their oil changed and their interiors detailed every now and then And you definitely don’t want to wait until a smoking sputtering engine strands you on the side of the Autobahn to finally call for help It’s been five months since the German government began imposing new lockdown measures last November to try to curb a steep rise in Covid-19 cases It seems as if all of Stuttgart has been blanketed in stifled feelings of frustration and loneliness and its warm rays offer a glimmer of hope that we will be able to enjoy biergartens with friends and make travel plans again While we may not be able to control when we receive the vaccine or when local governments will ease restrictions we can help ourselves to better face this new reality I didn’t think a weekend on Lake Constance learning about love languages could help my marriage thrive through a pandemic But those tools—resources we in the military community have at our fingertips when so many desperately need them and can’t afford them—can help us all make it through this tough time Editors Note: This <a target="_blank" href="https://thewarhorse.org/aperol-spritzes-and-dreams-of-post-pandemic-biergartens-in-lindau/">article</a> first appeared on <a target="_blank" href="https://thewarhorse.org">The War Horse,</a> an award-winning nonprofit news organization educating the public on military service Subscribe to their <a target="_blank" href="https://thewarhorse.us11.list-manage.com/subscribe/post?u=2dfda758f64e981facbb0a8dd&id=9a9d4becaa">newsletter</a> Metrics details The distinct pathological and molecular features of kidney cancer in adaptation to oxygen homeostasis render this malignancy an attractive model for investigating hypoxia signalling and potentially developing potent targeted therapies Hypoxia signalling has a pivotal role in kidney cancer particularly within the most prevalent subtype Hypoxia promotes various crucial pathological processes such as hypoxia-inducible factor (HIF) activation metabolic reprogramming and drug resistance all of which contribute to kidney cancer development are characterized by a loss of function of Von Hippel–Lindau tumour suppressor (VHL) leading to the accumulation of HIF proteins therapeutic strategies targeting pVHL–HIF signalling have been explored in ccRCC culminating in the successful development of HIF2α-specific antagonists such as belzutifan (PT2977) an FDA-approved drug to treat VHL-associated diseases including advanced-stage ccRCC An increased understanding of hypoxia signalling in kidney cancer came from the discovery of novel VHL protein (pVHL) targets and mechanisms of synthetic lethality with VHL mutations These breakthroughs can pave the way for the development of innovative and potent combination therapies in kidney cancer The tumour suppressor Von Hippel–Lindau protein (pVHL) which has vital functions in proteasomal degradation is predominantly lost or mutated in kidney cancer The pVHL–hypoxia-inducible factor (HIF) axis is a major oncogenic signalling pathway in clear cell renal cell carcinoma (ccRCC) have improved clinical outcomes in patients with ccRCC A group of newly identified pVHL downstream oncogenes provides potential novel therapeutic targets for ccRCC Targeting pathways showing synthetic lethality with VHL loss is an attractive and alternative strategy for treating ccRCC Combination therapies with hypoxia signalling inhibitors plus other therapeutic agents hold potential for the treatment of advanced or metastatic ccRCC Prices may be subject to local taxes which are calculated during checkout Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Landmarks in the diagnosis and treatment of renal cell carcinoma The 2022 World Health Organization classification of tumours of the urinary system and male genital organs – part a: renal Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicine Understanding the oxygen-sensing pathway and its therapeutic implications in diseases Tumor hypoxia: from basic knowledge to therapeutic implications VHL and hypoxia signaling: beyond HIF in cancer The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability Purification and characterization of hypoxia-inducible factor 1 a transcription factor selectively expressed in endothelial cells A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 alpha regulates the VEGF expression and is potentially involved in lung and vascular development Molecular characterization and chromosomal localization of a third ɑ-class hypoxia inducible factor subunit Cloning and expression of the human erythropoietin gene Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene Hypoxia-inducible factor-1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular O-2 tension Jr Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy Widespread hypoxia-inducible expression of HIF-2ɑ in distinct cell populations of different organs Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma HIF-ɑ effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma Jr Inhibition of HIF2ɑ is sufficient to suppress pVHL-defective tumor growth Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors HIF2ɑ-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma Jr Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis Genetic and functional studies implicate HIF1ɑ as a 14q kidney cancer suppressor gene HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation Role and regulation of prolyl hydroxylase domain proteins Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma Emerging targets in clear cell renal cell carcinoma Jr Targeting the HIF2–VEGF axis in renal cell carcinoma Targeting angiogenesis in renal cell carcinoma Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Sorafenib in advanced clear-cell renal-cell carcinoma Pazopanib versus sunitinib in metastatic renal-cell carcinoma Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial an angiogenesis inhibitor targeting VEGFR/FGFR shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 Integrated molecular analysis of clear-cell renal cell carcinoma VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5 HIF-mediated suppression of DEPTOR confers resistance to mTOR kinase inhibition in renal cancer Dissection of angiogenic signaling in zebrafish using a chemical genetic approach Efficacy of everolimus in advanced renal cell carcinoma: a double-blind A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer Randomized phase II trial of sapanisertib ± TAK-117 vs everolimus in patients with advanced renal cell carcinoma after VEGF-targeted therapy Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor Allosteric inhibition of hypoxia inducible factor-2 with small molecules Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma Targeting renal cell carcinoma with a HIF-2 antagonist On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models Proteomic analysis reveals diverse proline hydroxylation-mediated oxygen-sensing cellular pathways in cancer cells a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02293980 (2024) Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma Belzutifan for renal cell carcinoma in von Hippel-Lindau disease FDA approval summary: belzutifan for von Hippel-Lindau disease-associated tumors LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase III LITESPARK-005 study 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977) a hypoxia-inducible factor 2α (HIF-2α) inhibitor for the treatment of clear cell renal cell carcinoma US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04895748 (2024) US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05119335 (2023) Brugarolas, J. et al. Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001). J. Clin. Oncol. 40, https://doi.org/10.1200/JCO.2022.40.6_suppl.339 (2022) USP37 promotes deubiquitination of HIF2α in kidney cancer HIF2α-targeted RNAi therapeutic inhibits clear cell renal cell carcinoma HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans HIF-2ɑ downregulation in the absence of functional VHL is not sufficient for renal cell differentiation von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma Genome-wide screening identifies SFMBT1 as an oncogenic driver in cancer with VHL loss USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E ZHX2 inhibits proliferation and promotes apoptosis of human lung cancer cells through targeting p38MAPK pathway Transcriptional deregulation of homeobox gene ZHX2 in Hodgkin lymphoma ZHX2 inhibits thyroid cancer metastasis through transcriptional inhibition of S100A14 ZHX2 promotes HIF1ɑ oncogenic signaling in triple-negative breast cancer MBT domain proteins in development and disease The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition SFMBT1 functions with LSD1 to regulate expression of canonical histone genes and chromatin-related factors SFMBT1 facilitates colon cancer cell metastasis and drug resistance combined with HMG20A migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical cancer The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism Increased activated Akt expression in renal cell carcinomas and prognosis Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation Mitochondrial Akt regulation of hypoxic tumor reprogramming pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner a central kinase in innate immune sensing of nucleic acids and beyond Human TBK1: a gatekeeper of neuroinflammation Targeting TANK-binding kinase 1 (TBK1) in cancer TBK1 is a synthetic lethal target in cancer with VHL loss Therapeutic targeting of the hypoxic tumour microenvironment Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases Identification of RIP1 kinase as a specific cellular target of necrostatins Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state Hypoxia stabilizes SETDB1 to maintain genome stability von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Contrasting effects on HIF-1ɑ regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease NEDD8 acts as a ‘molecular switch’ defining the functional selectivity of VHL The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis Basement membrane regulates fibronectin organization using sliding focal adhesions driven by a contractile winch The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells Matrix metalloproteinase-2 and -9 lead to fibronectin degradation in astroglia infected with toxoplasma gondii Matrix metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin A group of interacting yeast DNA replication genes Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster Synthetic lethal therapies for cancer: what’s next after PARP inhibitors Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors VHL synthetic lethality signatures uncovered by genotype-specific CRISPR-Cas9 screens Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma Exploring synthetic lethal network for the precision treatment of clear cell renal cell carcinoma The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species CDK4 and CDK6 kinases: from basic science to cancer therapy Treating cancer with selective CDK4/6 inhibitors CRISPR/Cas9 for cancer research and therapy Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma Resistance to targeted therapy in renal-cell carcinoma HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1ɑ and HIF-2ɑ balance in renal cell carcinoma Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04627064 (2024) McDermott, D. F. et al. LITESPARK-024: a randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma. J. Clin. Oncol. 41, https://doi.org/10.1200/JCO.2023.41.6_suppl.TPS747 (2023) PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC Synergy between tumor immunotherapy and antiangiogenic therapy Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3 Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03324373 (2024) Multi-level interaction between HIF and AHR transcriptional pathways in kidney carcinoma Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells Optimized combination of HDACI and TKI efficiently inhibits metabolic activity in renal cell carcinoma and overcomes sunitinib resistance Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors Download references Kidney cancer research in Zhang lab is supported by the National Cancer Institute (R01CA211732 and R01CA284591) Department of Defense Kidney Cancer Research Program (W81XWH1910813) and Cancer Prevention and Research Institute of Texas (CPRIT was an American Cancer Society Research Scholar Komen Career Catalyst awardee and Mary Kay Foundation awardee was also previously supported by Kidney Cancer Research Alliance (KCCure) These authors contributed equally: Chengheng Liao University of Texas Southwestern Medical Center All authors contributed substantially to discussion of the content All authors reviewed and/or edited the manuscript before submission received the consultation fee from Exelixis The other authors declare no competing interests reviewer(s) for their contribution to the peer review of this work Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law Download citation DOI: https://doi.org/10.1038/s41585-024-00876-w Sign up for the Nature Briefing newsletter — what matters in science Please select what you would like included for printing: Copy the text below and then paste that into your favorite email application Patricia dedicated over 20 years of her life to Deluxe Check where she made her mark as the sole female on the production line Her commitment and perseverance served as an inspiration to many she pursued higher education and achieved a degree in psychology in her 50s Patricia was a woman of many talents and passions From Christmas baking to crafting and gardening she found joy in the simple moments of life Her strong-willed nature was evident in everything she did but it was her unwavering love for her family that truly defined her Patricia's memory will forever be cherished by all who knew her She faced the challenges of dementia with grace and peace until the end She is preceded in death by her parents Fabien and Ann Patricia is survived by her children Jennifer Lindaux William (Melissa) Lindau; grandchildren Annie (Carey) Jameson; along with many nieces and nephews Pat's family wishes to express their gratitude for all who so lovingly cared for their mother including the nurses from HealthEast Hospice and the entire staff of the 4th floor at Cerenity Marian Her life will be honored and celebrated at the following services: - Visitation on May 3rd at Cerenity Senior Care Marian - St - Mass on May 3rd at Cerenity Senior Care Marian - St - Interment at Evergreen Memorial Gardens on May 3rd at 1:30 PM Enter your phone number above to have directions sent via text This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply Service map data © OpenStreetMap contributors